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DEVELOPMENT OF QUANTITATIVE BIOANALYTICAL METHODS FOR THE
MEASUREMENT OF PHARMACEUTICAL ANALYTES VIA HPLC-UV AND
HPLC-MS/MS
MELISSA A. McCULLOCH
ABSTRACT

Research in pharmaceutical treatments for illnesses and disease
processes has rapidly grown in the past decade. The field is fueled by advances
in our understanding of the molecular mechanics of the human body, coupled
with the development of sophisticated scientific instruments which can efficiently
generate massive amounts of important data. This has led to an ever-growing
need for the development of quantitative bioanalytical methods to measure
pharmaceutical compounds.
In this work, the theory behind the analytical processes and instruments
that make these investigations possible is discussed. Further, the development
of two high performance liquid chromatographic (HPLC) methods with both ultra
violet (UV) spectrometry and mass spectrometry (MS) detection of the
cannabinoid (CB) antagonists‟ rimonabant and surinabant is presented. The
methods developed for the CB antagonists‟ are successfully applied to animal
studies in clinical and pre-clinical investigations. Thirdly, preliminary work is
included which was conducted for the development of two methods to be used in
the measurement of anti-cancer agents, quinacrine and triapine. Finally, a
discussion is presented for the consideration of the challenges and potential
solutions in the development of an HPLC-MS method for triapine.
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The theory, experimental designs and results discussed here
demonstrates how analytical chemistry and instrumentation are used in
bioanalytical method development. This research also illustrates how once
developed, these methods serve to advance the progress in biochemical,
preclinical and clinical studies.
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CHAPTER I

INTRODUCTION TO BIOANALYTICAL METHOD DEVELOPMENT:
PHARMACEUTICAL COMPOUND EXTRACTION, HIGH PERFORMANCE
LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY

1.1 Rationale for Method Development

The development of analytical methods to quantitate drug molecules is critical
to the progress of toxicological, biochemical and clinical studies. Methods must
be established and validated to demonstrate robustness, precision and accuracy
of the ability of the method to determine the amount of drug present in the
sample of interest. The ability to ascertain the amount of drug present provides
the research community with the ability to establish the pharmacokinetics, or how
the body processes the drug [1], as well as the pharmacodynamics [1], how the
drug affects the body.
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Pharmacokinetic parameters are divided into several sections, referred to as
a LADME scheme [2]: liberation, absorption, distribution, metabolism and
excretion. Liberation refers to the manner which the drug is released from the
formulation. Absorption deals with how the drug is introduced to the body.
Distribution is the dispersion or dissemination of the drug within the bodily fluids
and tissues. Metabolism describes the transformation of the original drug into
metabolites. Excretion refers to how the drug is removed from the body.
Pharmacodynamics consists of three principle components [3]: the desired
affects of the drug, undesired affects of the drug and the therapeutic window of
the drug. Desired affects of a drug can be caused by a variety of biochemical
processes, including: chemical reactions, interaction with proteins, interaction
with ion channels and ligand binding. There are also many situations which
produce undesirable effects of a drug, including: mutagenic or carcinogenic
cellular response, as well as, inducing cellular damage which can lead to chronic
biological and physical abnormalities. Finally, the therapeutic window can be
though of as the effective dosing, or the dosing amount that provides more
desirable effects versus undesirable effects.
In order to study the behavior of a drug within an animal body, it is necessary
to establish bioanalytical methods. There are several important considerations
for the methods being developed: cost, an effort should be made to favor
consumables which are the least expensive; time, the total sample preparation
and run time should be kept to a minimum to enable high throughput of the
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method; simplicity and transferability, the method developed should avoid over
complication.

1.2 Extraction of Pharmaceutical Compounds from Biological Matrices

1.2.1 Introduction

Bioanalytical methods allow the detection of small amounts of a drug within a
complex biological matrix, commonly plasma, urine, saliva or tissue. The
biological materials are composed of a vast array of compounds, with varying
chemistries. In order to detect trace amounts of pharmaceutical compounds
present in these materials, the compounds must be removed from the remaining
compounds in the sample.
The first step in the development of a method is the extraction or removal of
the compound from the biological matrix. The matrix of blood will be discussed
here. Blood is composed of red blood cells, approximately 45% by volume,
which are suspended in plasma fluid (55% by volume). Plasma is approximately
92% water and 8% plasma proteins and other compounds such as minerals,
glucose, carbon dioxide, hormones and pharmaceutical compounds [4].
Prior to analytical treatment, whole blood undergoes several pretreatment
steps to separate the plasma from the red blood cells. First and anticoagulant is
added to whole blood to prevent clotting. Secondly, the red blood cells are
separate from the plasma via centrifugation. In addition to the red blood cells,
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many plasma proteins will be removed from the plasma during this step. The
protein in highest abundance remaining in the plasma is albumin. In addition to
albumin, the plasma matrix consists of many compounds, including other
proteins, minerals, electrolytes (salts), glucose, carbon dioxide, hormones and
pharmaceutical compounds [5].
Although many potentially interfering substances have been removed from
the whole blood, the reduction of matrix components remaining in the plasma will
improve the sensitivity of developed method for the compound of interest.
Further, salts, proteins, and various chemical species remaining can create
contamination as well as negatively affect the precision and accuracy of the
method ability to detect the pharmaceutical compound. There are many popular
suitable chromatographic methods which are a good choice for removing the
pharmaceutical compound from the biological matrix. Common types of
chromatography used for this purpose include: liquid/liquid extraction, protein
precipitation, and solid phase extraction.

1.2.2 Liquid Liquid Extraction (LLE)

LLE is based on partitioning of compound into two separate liquids. LLE
works by exploiting the solubility of an compound in two immiscible liquids,
generally an aqueous and an organic. Organic solvents with low polarity are
generally immiscible with water. For instance, toluene, diethyl ether and hexane
not miscible and less dense than water, forming a partition that floats on top of
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the aqueous phase. Chloroform and methylene chloride are immiscible and
more dense than water, forming a partition underneath the aqueous phase.
The distribution or partitioning of an compound (solute) between the two
phases in LLE can be represented by the following equilibrium equation,
equation (1) [6]:
Solute (aqueous phase)

Solute (organic phase) (1)

Therefore, the equation describing the partition coefficient, the ratio of species in
each respective phase can be written as equation (2) [6]:

Kp = [Sorganic] / [Saqueous]

(2)

Evidenced by equations 1 and 2, the amount of analyte in each phase is an
equilibrium process and for any Kp value, there will remain an amount of analyte
in the aqueous phase. The equation describing the amount of analyte remaining
in the aqueous phase after n injections is given in equation (3) [6]:

qn = [V2/(V2+KpV1)]n

(3)

where q is the fraction of S remaining in the aqueous phase, V1 is the volume of
the organic phase, V2 is the volume of aqueous phase and Kp is the partition
coefficient. In order to achieve quantitation removal of an analyte, several
extractions are often required.
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organic

aqueous
vortex

Figure 1.1, Representation of LLE
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1.2.3 Protein Precipitation

Protein precipitation bears many similarities to LLE. Consider a plasma
sample which contains an analyte to be extracted, in addition to the analyte;
there are countless proteins, salts, metals and other compounds present in the
plasma sample. Proteins contain both hydrophilic and hydrophobic amino acid
residues. When dissolved in water, the hydrophilic amino acids are oriented so
as to interact with the polar, aqueous phase. In the case of hydrophobic amino
acids, they interact with various ions in the solution to stabilize the proteins
solubility in the aqueous phase [7].
There are two types of forces acting upon a protein molecule in an aqueous
solution, repulsive electrostatic force and attractive electrostatic force. Repulsive
electrostatic forces are demonstrated in figure 1.2. Further detail describing the
solvation (or hydration) layer of proteins is contained in figure 1.3.
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Figure 1.2, Depiction of electrostatic forces present in protein solutions
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Figure 1.3, Ion distribution in the hydration layer of a protein solution
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The repulsive forces between proteins prevent the proteins from interacting
with another and promote the dissolution of the proteins in the aqueous solvent.
This phenomenon occurs because counter ions migrate to the surface of the
protein molecules and form a rigid barrier, effectively neutralizing the surface of a
charged molecule. Beyond the rigid counter ion barrier, ions continue to migrate
in increasingly lower concentrations. This loose, charged barrier around the
proteins, allow the protein molecules to remain dissolved in solution while, at the
same time, prevent the aggregation of protein molecules into clusters. Water
itself can serve to generate the barrier surrounding the proteins [7].
Attractive electrostatic forces exist due to induced or permanent dipoles of
protein molecules. A general illustration of attractive electrostatic forces is
contained in figure 1.4. One example of an attractive electrostatic force between
proteins would be the interaction of acidic residues on one protein with basic
residues of another. The solvation of the proteins by the hydration layer serves
to disrupt the attractive forces between proteins [7].
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Figure 1.4, Hydration layer disruption caused by protein-protein
interactions
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Protein precipitation occurs in several steps: addition of precipitating
agent, mixing and precipitate formation. Commonly an organic solvent such as
acetonitrile or methanol is used as the precipitation agent. Upon the addition of
these solvents, the solution looses stability. The unstable solution will cause
denaturation of proteins and the mixing will cause the denatured proteins to
aggregate and to precipitate from the plasma solution. Based on the size and
weight of the precipitated proteins, they begin fall to the bottom of the extraction
vessel. Further, many salts are not soluble in the organic solvents and therefore
also precipitate out of the plasma solution. The precipitated proteins can further
be separated from the extraction solvent via centrifugation. Once centrifuged,
the organic supernatant can be evaporated and thereafter reconstituted in order
to control the concentration.
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Supernatant

Vortex

Vortex

200 μL
Plasma

50 μL AA
10 μL IS
10 μL Std

1 mL ACN

Figure 1.5, Protein precipitation procedure
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Centrifuge
15 min
10,000 rpm

1.2.4 Solid Phase Extraction (SPE)

SPE is a widely used chromatographic method to separate an analyte from a
complex matrix. In SPE, a column is packed with a stationary phase which will
retain the analyte of interest. Commonly, the stationary phase, or sorbent is
composed of a carbon based packing material as C18 and C8. There are
generally four steps in SPE, sorbent conditioning, sample loading, rinsing and
sample elution [8]. A block diagram demonstrating a general SPE process is
contained in figure 1.6.
Step one is to activate the sorbant by rinsing with an organic solvent in order
to wet the stationary phase. The hydrophobic packing is dry initially and the
ligands are all collapsed. Organic phase extends the ligands and prepares them
for interaction with the analyte [8].
Step two of SPE is the sample loading phase. A solution containing the
sample, as well as, any contaminants or interfering substances, is introduced
onto the stationary phase. The stationary phase will interact with the analyte
molecules, retaining them until step four.
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Figure 1.6, SPE procedure
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Step three of SPE is a washing step which aids in the removal of
contaminants and interfering compounds. This step is conducted again with the
solvent composition of the sample matrix. During this step, the analyte will be
bound by the stationary phase and will not be released by the column.
Finally, in step four of SPE, an elution solvent is introduced to the column.
The elution solvent will have distinctly different properties than the solvent used
for the previous three steps. For example, considering a hydrophobic
pharmaceutical compound: should the sample be loaded in an aqueous plasma
solution, an organic solvent such as acetonitrile may be used to elute the
compound. As in LLE, the elution solution collected may be evaporated in order
to control the concentration.

1.3 High Performance Liquid Chromatography (HPLC)

1.3.1 Introduction

HPLC is a cornerstone of bioanalytical chemistry which began development in
the 1970‟s. HPLC can be used to separate, identify and quantitate and any
compound which can be dissolved in a liquid. HPLC is not bound by sample
volatility or thermal stability, is conducted at room temperature, is able to be
automated, provides ease of use, and generates powerful data.
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Many forms of HPLC exist, including: normal phase, reverse phase, ion
exchange, size exclusion and bioaffinity, to name a few. It is important to
differentiate between normal and reverse phase chromatography. In the case of
normal phase, the compound of interest has a polar, or hydrophilic chemical
composition. Chromatographic conditions for normal phase would utilize a polar,
hydrophilic analytical column and mobile phase composition. The vast majority
of pharmaceutical compounds investigated are either non-polar, hydrophobic or
both. Due to the chemical nature of pharmaceutical compounds, reverse phase
HPLC is typically used. In reverse phase HPLC, the hydrophobic interactions
between the analyte and the column are manipulated and the mobile phase
typically has a strong organic component [9].
The work described here deals exclusively with reverse phase HPLC, the
most popular type currently used in bioanalytical method development for drug
compounds, all references to HPLC will be in respect to reverse phase HPLC.
There are five (5) principle components to an HPLC system, the mobile phase,
pump, injector, column and detector. A flow diagram of an HPLC system is
contained in figure 1.7. A in depth discussion of each component follows.
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mobile
phase

pump

column

injector

Figure 1.7, Flow diagram of HPLC setup

18

detector

1.3.2

Column Selection

In today‟s entrepreneur driven society, there are countless manufacturers of
columns to be used in bioanalytical method development for the detection of
pharmaceutical analytes. The discussion that follows will consider only columns
suitable for reverse phase chromatographic separations. Within the different
manufactures of columns, there exists a broad array of column chemistries. The
most widely used columns utilize carbon based chemistry in design, for example
C18, C8 and C4. A successful column will allow for suitable resolution of the
analytes of interest, low backpressure generation, minimal solvent consumption
and short analysis times.
In respect to column choice the most important phenomenon to avoid is band
broadening. Band broadening lowers the number of theoretical plates in a
column thereby reduces the separation power of a column. There are three
factors which contribute to band broadening: longitudal diffusion, resistance to
mass transfer across phases (stationary and mobile), and eddy diffusion which is
caused by mobile phase factors.
Longitudal diffusion is diffusion of the sample in a direction parallel to the
sample flow.
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Figure 1.8, Figural depiction of longitudal diffusion
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As evidenced in figure 1.8., the longer a solute remains in a column the more
a sample diffuses and the broader the peak shape becomes. The length of time
a solute remains in a column has an inverse relationship to the mobile phase flow
rate and therefore the longitudal diffusion is also inversely proportional to the
mobile phase flow rate. The equation relating the longitudal diffusion (σ L2) to the
length of the column (L) is given in equation x., where Dm represents the
diffusivity of the solute in the mobile phase u is the linear velocity of mobile phase
and γ is a constant that depends of the column packing material [10].

σL2 = (2DmL γ) / u

(4)

As evidenced in equation 4, band broadening due to linear diffusion can be
reduced by manipulating the mobile phase flow rate and the column length.
A second factor affecting band broadening is the resistance to mass
transfer across the boundaries of both the stationary and mobile phase [11].
Figure x is a simple graphical depiction of how mass transfer can cause band
broadening.
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Figure 1.9, Mass transfer due to (A) resistance in the mobile phase and (B)
resistance in the stationary phase
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In figure 1.9(A) it is evident that in the beginning, all analyte molecules occupy
a small horizontal space. During this time, some of the analyte molecules are
transferred from the mobile phase to the stationary phase, this process is
dictated by the spatial proximity of the molecules to the stationary phase. It will
take longer for molecules that are further a longer time to interact with the
stationary phase. This time results in band broadening. The same scenario can
be considered for the molecule bound to the stationary phase as depicted in
figure 1.9(B). While the molecules initially are confined to a narrow horizontal
space, it will require time for the molecules a greater vertical distance from the
boundary of the phase to migrate to that surface and interact. Again, the
resistance to mass transfer causes band broadening.
The last phenomenon that causes band broadening is eddy diffusion [11].
Eddy diffusion is the uneven flow distribution of a mobile phase through a
stationary phase. This form of diffusion is not well described using a
mathematical equation.
Besides the considerations discussed regarding band broadening and the
various diffusions that cause it, there are other factors to consider in column
choice. Overall the parameters are column length, particle size, column
diameter (internal diameter), and pore size [12, 13].
In respect to column length, the longer a column, the higher the resolution
power. However, as column length increases, the backpressure increases which
can be unpractical for many HPLC systems. Generally for reverse phase HPLC
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analysis of pharmaceutical analytes, columns under 5cm will provide suitable
resolving power with limited backpressures.
The smallest particle size practical should be chosen for column material.
Currently, standard sizes are 5μm with the smallest size available being 2μm.
The smaller the particle size, the more theoretical plates per unit length of
column, which is a desirable feature. Additionally, small particle sizes allow for
faster column equilibration with mobile phase as well as, faster analysis times.
Common column internal diameters are 4.0-4.6 mm. In this range of
internal diameters, the columns can withstand flow rates in the range of 1.0 1.25
mL/min. Narrow bore columns are available with internal diameters in the range
of 2.0 to 3.0 mm. These columns can withstand flow rates in the range of 0.2 to
0.6 mL/min. The narrow bore columns are advantageous because their use
reduces solvent consumption as well as, improves sensitivity.
In respect to pore size, the smaller the pore size, the larger the surface
area and therefore the greater carbon loading of the column. In the case of
pharmaceutical analytes, the optimum pore size is in the range of 80-150 Å.
In general, for reverse phase HPLC analysis of pharmaceutical analytes, a
carbon based column will be a good choice. A carbon based column is
composed of silica molecules which are bonded to a carbon chain. The length of
the carbon chain typically ranges from C4 to C18. As the carbon chain length
increases, the hydrophobicity of the stationary phase also increases. A common
defect of carbon columns is related to unreacted silanol groups in the stationary
phase. This defect is remedied via a process called endcapping where the
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unreacted silanol groups are reacted through various chemical processes.
Each manufacture has unique, proprietary endcapping techniques.

The

process of endcapping reduces the possibility of undesired, secondary reactions
between analytes and the stationary phase. Finally, carbon based columns allow
for the use of a wide range of mobile phases; including water, acetonitrile and
methanol; as well as a wide pH range.

1.3.3. Mobile Phase Selection

The selection of a mobile phase is multifaceted: the solvent must be able to
elute the analyte with sufficient resolution, the resolution time of the analyte
should be low enough to allow for highthroughput, the use of additives such as
buffers and acids should be kept to a minimum and the organic component
should be chosen with cost in mind. There are endless possibilities for mobile
phase compositions; it is helpful to consider two (2) primary features affected by
formulation of mobile phase: solvent polarity and solvent selectivity [11, 12]. The
equation describing the relationship between solvent polarity and solvent
selectivity is contained in equation 5.

Rs = √N/4 (α-1/α) (k‟/1+k‟)
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(5)

In equation 5, the term (α-1/α) represents the solvent selectivity factor and the
(k‟/1+k‟) is the solvent polarity term, √N/4 is the column factor, and Rs is the
resolution value. Table I. lists the properties of several common solvents.
The relationship between the polarity index of a solvent and the polarity term
given in equation 4 for a reverse phase system is given by equation 6.

k„2/ k„1 = 10 ^ [(P‟2 – P‟1)/2]

(6)

The values of k‟ are initial and final values and are related to the retention time tr
of an analyte and the retention time of the unretained solvent (solvent front) t 0
given by equation 7.

k‟ = tr – t0/t0
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(7)

Table I Properties of common solvents

Solvent

Viscosity, cP

water

Refractive
◦
Index (25 C)
1.333

0.89

Boiling
◦
Point, C
100

Polarity
’
Index, P
10.2

Elutent
0
Strength, є
Large

acetonitrile

1.341

0.34

82

5.8

0.65

methanol

1.326

0.54

65

5.1

0.95

n-Hexance

1.372

0.30

69

0.1

0.01

toluene

1.494

0.55

110

2.4

0.29

ethyl acetate

1.370

0.43

77

4.4

0.58

chloroform

1.443

0.53

61

4.1

0.40
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A successful mobile phase composition should aim for a k‟ value between 2
and 5 for a two component system and for a k‟ between 0.5 and 20 for a multiple
component system [14}. After the solvent composition of mobile phase is
optimized fro k‟, generally the analytes will be suitably resolved. In the case that
the retention times of the analytes continue to overlap, α, the selectivity factor
can be manipulated. The typical approach to optimizing the selectivity factor is to
change the chemical composition of the mobile phase while holding the k ‟
constant. Equation 8 [14] demonstrates the approach to changing the selectivity
of a mobile phase without having an effect on the k‟ for a reverse phase system.

Фc = [[Фb (Pw –Pb)]/ (Pw –Pc)]

(8)

In equation 7, there are three solvents to consider: W, water; B, the organic
component that is being changed and; C, the organic component that is replacing
B. In this equation, Фc represent the %volume of solvent C; Фb is the volume of
the organic component B; and Pw, Pb, and Pc represent the polarity indexes of
water, solvent B and solvent C, respectively.
As evidenced by the preceding discussion, through the use of a handful of
simple equations, it is possible to both predict and adjust the chromatography
results based upon mobile phase composition.
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1.3.4 Pump

The goal of a pump is to provide the most constant flow possible of mobile
phase to the column. Due to the small particle sizes of column packing material,
there is a great resistance to the flow being delivered to the system. The “HP” of
HPLC originally represented “high pressure” because of the high pressure which
is generated during this process. There are several types of high pressure
pumps which can be coupled to HPLC systems. Due to the vast number of
pump types available, a summary list of pump types and their characteristics is
contained in Table II. [14].

29

Table II., Performance characteristics of different types of pumps

Simple
singlehead

Single–head
Simple
pulse comp. Dual-head

Reciprocating pumps

Pump
characteristic

Positive displacemen
t
Dual-head compress Dual-head Triple-head, Syringe
corrand pulse comp closed loop low volume type
flow control

Pneumatic

Hydraulic Simple Amplifier Amplifier with
amplifier
flow control

+

++

+
+

+

+

-

-

+

++

++

-

-

+

high

++
++

-

++

++

+

++

mod

++

++

+

++

++

++

-

+

+

low

++

++

-

++

++

++

-

mod

+

++

+

+

+

++

++

+

Resettability

+

+

very high

+

+

++

+

-

+

+

very high

+

+

++

+

++

+

+

high

++

_

+

+

++

+

+

mod

++

Short term
precision
(“noise”)
_

+

+

Accuracy

+

mod

+

Versatility and
convenience
+

+

Serviceability
low

Drift

Cost

Durability

no

no

no

yes

yes

yes

yes

yes

no

modhigh
yes

no

yes

yes

yes

yes

no

yes

no

yes

no

no

“Constant
”
flow

no

Constant
pressure

Notation: ++ = optimum, + = satisfactory,
- = some deficiencies
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1.3.5 Injector

With respect to injectors, there are four primary considerations: the
sample should be introduced to the column via a narrow plug; the injector should
be easy to use; the results should be reproducible from injection to injection and;
the injector should be able to operate at a high back pressure.
Typical sample loop sizes range from 5 to 50 μL. In order to avoid problems
related to dilution, the sample loop should be overfilled by at least three loop
volumes.
Most modern HPLC instruments are coupled with automatic sample
injectors, or autosamplers. The injections are controlled by a computer and
robotic instrumental components which diminishes most error introduced during
the injection process.
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Figure 1.10, Example of injector port
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1.3.6 Detector

A vast array of detectors can be coupled to HPLC systems. A summary of
popular detectors and their detection limits is contained in Table III. [14]. The
research presented here focuses on two types of detectors, the ultraviolet
detector and mass spectrometer, both of which are described in great detail in
future sections.
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Table III. Detection limits achievable using various detectors

Detector

~ Limit of detection (ng)

Ultraviolet

0.1-1

Refractive index

100-1000

Evaporative light scattering

0.1-1

Electrochemical

0.01-1

Fluorescence

0.001-0.01

Conductivity

0.3

Mass spectrometry

0.1-1

Fourier transform infared

1000
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1.4 Ultraviolet (UV) Spectroscopic Detectors

1.4.1 Introduction

UV spectroscopic detectors are one of the most widely used detectors
coupled to HPLC systems. These detectors offer ease of use, are available for
relatively low cost, allow for excellent linearity and provide sensitivity at a level
suitable for a wide range of applications. The principle limitation of the UV
detector is the requirement that the analyte absorb light in the range of 200 –
350 Å. This range includes all substances that have at least one double bond as
well as any substance possessing non-bonded electrons, this group consists of
all aromatic compounds, and substances containing CO, CS, N=O groups. As
can be imagined, most pharmaceutical analytes belong to the group of
compounds which will absorb light in the range required to use the UV detector.

1.4.2 Beer-Lambert Law

The Lambert law states that the absorption of light is directly proportional to
the path length traveled. Beer‟s law states the relationship between the
absorption of light and the concentration of analyte. Together, the Beer-Lambert
law dictates the results afforded in UV spectroscopy. The equation for the BeerLambert law is given in equation 10.
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A=ξ

lC

(10)

Where A represents absorption, ξ is the molar absorptivity, a constant, l is the
path length that the light travels, and C is the concentration of analyte.

1.4.3 Types of UV Detectors

There are two types of UV detectors, fixed wavelength and multiple
wavelength detectors [15, 16]. Fixed wavelength detectors operate on a single
wavelength of light that is generated from a specific type of lamp. These lamps
can be mercury (254 nm), cadmium (225 nm), and zinc (214 nm). It is important
to note that while these lamps generate the majority of light at the wavelengths
listed, there is a range of wavelengths emitted, in order to achieve true
monochromatic light, a filter would be required.

36

Figure 1.11, Fixed wavelength UV detector
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A multi wavelength detector emits light over a broad range of wavelengths.
Within the category of multi wavelength detectors, there are two types: the
dispersive detector and the diode array detector. The dispersive detector
monitors the elutent at a single wavelength while the diode array examines the
elutent over a wide range of wavelengths.
Figure 1.12 illustrates a dispersive detector. In this detector light is
generated from either a deuterium or xenon lamp and is focused by a curved
mirror onto a diffraction grating. The light is dispersed and refocused onto a
plane mirror, the angle of tilt of the mirror is able to control the wavelength of light
emitted which then travels through the sample cell and column elutent.
Commonly a wavelength is chosen based on a range of wavelengths that a
particular analyte is known to absorb.
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Figure 1.12, Multiple wavelength UV detector
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Diode array detectors also use deuterium or xenon lamps, however, the path
that light takes differs greatly from the dispersive detector. The light generated
by the lamp passes through a lens system and is then directed through the flow
cell, permitting light of all wavelengths to pass through the column elutent and
onto a holographic grating. Light then travels to a photo diode array which can
contain a large amount of diodes. Each diode is regularly sampled and a
computer reports the output. Once the spectra is finished being recorded, it is
possible to go back and review the data generated from any particular diode,
depending on the wavelength(s) of interest.
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Figure 1.13, Diode array detector
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1.4.4 Concluding Remarks

As discussed, UV detectors are suitable for a wide range of applications. The
instrumental setup provides an ease of use that is remarkable when the power of
data generated is to be considered. The linear range afforded by either the fixed
or multi wavelength detector is in the range of 5 x 10-8 to 5 x 10-4 g/mL. Further,
an average HPLC with UV detector can be purchased for under $100,000, which
puts these instruments within the financial grasp of many researchers.

1.5 Mass Spectrometric (MS) Detectors

1.5.1 Introduction

Mass spectrometers are arguably the most powerful instruments available
to the analytical chemist today. The data generated via these instruments is able
to both qualitate and quantitate chemical species, provide structural elucidation,
as well as elemental analysis for compounds. There are many types of mass
spectrometers including: triple quadrapole (QQQ), ion trap (IT) and time of flight
(TOF).
Mass spectrometers work by detecting a signal based on a mass to
charge (m/z) ratio for ionized compounds. A mass spectrum is a graph of the
intensity of ions versus the mass to charge ratio.
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There are four principle steps carried out by the components of a mass
spectrometer: ionization, acceleration, deflection and detection [17]. An ion
source causes the analyte compounds to enter the gas phase. A mass analyzer
is equipped with sophisticated electronics which accelerate and deflect or focus
the ions. Finally, a detector measures the ion signal produced from the
preceding components.

1.5.2

Ion sources

Ion sources vary widely and are dependant upon the type of material which
needs to be ionized. The ion source can be viewed as the most important of the
mass spectrometers components, without successful ionization there will be no
analyte to be focused in the mass analyzer and thereafter detected.

Some of

the many types of sources include: electron ionization (EI), chemical ionization
(CI), atmospheric pressure ionization (API), and electrospray ionization (ESI). A
brief discussion of the theory involved in each of the four ionization methods
mentioned follows, however, this work described here focuses primarily on ESI,
which will be considered in more detail.
In electron ionization (EI) a beam of electrons passes through an electric field
and gains energy. The accelerated electrons interact with the analyte molecules
causing the analytes to form ions and ion fragments. Representative reactions
are contained in equations 11 and 12. In equation 11, a neutral analyte forms a
radical cation. In some situations the interaction with accelerated electrons
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causes the ion formed to possess such an amount of energy that it is further
fragmented, which is depicted in equation 12 [17].

e- + M → M•+ + 2e-

(11)

e- + M → M•+ + 2e-+ A+ +B+, etc.

(12)

In these equations x and x, e- represents an electron, M represents the analyte
and A+ and B+ are the fragments produced from M•+.
Chemical ionization (CI) is quite similar to EI, the first ionization step being
the same. However, the steps following the initial ionization are different.
Chemical ionization uses a flow of reactive gas, often methane (CH4) to react
with an electron beam. In CI, the analyte (M) is present in relatively small
amounts in the collision gas, therefore the electrons interact more strongly with
the gas molecules (R) which are in higher concentration. The electron interaction
creates a high concentration of gas ions (R•+), it is the gas ions that then interact
with the analytes (M). A representative equation demonstrating the ionization
process in CI is contained in equation 13 [17].

R → R+ → RH+ + M → MH+ + R
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(13)

CI can be thought of as a more soft ionization process compared with EI and is
often favored because often EI generates all fragments, resulting in the absence
of analyte ions.
Atmospheric pressure ionization (API) differs primarily from CI and EI in
that with both CI and EI, the ionization process occurred in the gas phase,
therefore any compound to be analyzed must first be vaporized. Contrary to CI
and EI, API is a method of ionizing nonvolatile species. Although API differs
from CI, there are many similarities and API is sometimes referred to APCI, or CI
conducted under atmospheric pressure. A diagram which illustrates API is
contained in figure 1.14 [19].
In API the analyte and solvent flow from a discharge needle and are exposed
to a nebulizing gas at atmospheric pressure. Heat is applied to the liquid flow via
a drying gas and further aids in the vaporization of the solvent and analyte
molecules. Within the heated source is a corona discharge needle which applies
a voltage, ionizing the solvent molecules. The ionized solvent molecules then act
similar to the process of CI, where collisions and charge transfers generate
ionized analytes. API or APCI, is often favored in high molecular weight,
biological molecules such as proteins, oliogosaccharides, and oligionucleotides.
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Figure 1.14, API ionization
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The final ionization method to be discussed is by far the most commonly used
and the most widely applicable. Electrospray ionization (ESI) is similar to API in
that a liquid is subjected ionization at atmospheric pressures, however in ESI, the
actual ionization is not a chemical ionization procedure [18].
In ESI, a solution is pumped through a capillary at a low flow rate, the optimal
flow rate is a design feature of each instrument, in the work presented here it is
should be less than 100 μL/min. The capillary is subjected to a high voltage, and
can be positive or negative, depending on the analyte of interest. The voltage
applied to this capillary facilitates the formation of an electrical gradient and
promotes charge separation; the result is the droplets emerge from the tip of the
capillary in a formation known as a Taylor cone. The charged droplets emerge
from the Taylor cone formation and travel towards the entrance to the mass
spectrometer.
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Figure 1.15, ESI ionization
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Once droplets have emerged from the tip of the capillary, they are ionized
through a process which has been described with various theories. The coloumb
fission mechanism asserts that as the solvent evaporates, there is an increase in
charge density around the droplets which causes large droplets to break into
smaller droplets, eventually resulting in singly charged ions. A second
mechanism of ionization, ion evaporation, states that the increased charge
density caused by solvent evaporation causes an electric repulsion that provides
the force to overcome the surface tension of the droplet and ions are released.
ESI is a suitable ionization technique for the analysis of a wide range of
compounds. The relatively “soft” ionization process deems it a method of choice
for high molecular weight biological compounds as well as, small drug molecules.
As mentioned, the majority of pharmaceutical compounds tend to be non polar
and ESI is generally more successful with non-polar compounds versus polar
species.
In conclusion, it is important to note that during ESI-MS instrumental
development, the pursuit of lower detection limits and increased sensitivity
focuses on the design of the ESI source to improve ion transmission. Further,
instrumental parameter which is critical to successful ion transmission is the flow
rate of liquid entering the ion source.

1.5.3

Mass Analyzers

The mass analysis component of a mass spectrometer serves to sort
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through the ions produced in the ion source so that only the ions of a specific
mass or mass range are detected. There are several types of mass analyzers
available including: single quadrapole, triple quadrapole, quadrapole ion trap,
time of flight and magnetic sector. A table highlighting the characteristics of
several types of mass analyzers is contained in table IV. [20]. The work
presented here focuses on two types of analyzer, the triple quadrapole (QQQ)
and the quadrapole ion trap (IT), the discussion presented will be limited to these
types of analyzer.
Both the QQQ and the IT possess a quadrapole design. The quadrapole
consists of four metal rods, aligned parallel to one another. Each pair of
opposing metal rods is connected electronically and a radio frequency (RF)
voltage is applied between them. A direct current voltage is then applied,
superimposed upon the RF voltage. The currents applied to the metal rods
generate an electric which focuses the ions based on their mass to charge (m/z)
ratio. As evidenced in figure x. only ions of a specific m/z ratio will be resonant
and permitted to pass through the quadrapole. The remaining ions are deflected
out of the quadrapole and therefore, not detected [17].
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Table IV., Properties of various mass analyzers
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In the case of a QQQ mass analyzer, three quadrapole are arranged in
sequence. As depicted in figure 1.17, the QQQ design is composed of three
quadrapoles arranged in series. The first (Q1) and third (Q3) quadrapoles serve
as mass filters, with the second (Q2) acting as a collision cell. In Q1, voltages
are applied to select for the m/z ratio or range of m/z ratio of the analyte of
interest, the remaining m/z ratios are deflected and do not pass to the Q2. The
ions which pass from Q1 to Q2 are commonly referred to as parent ions.
In the Q2, or collision cell, a collision gas is introduced to the analytes that
have entered from Q1. The collision cell does not have mass filtering capacity;
an RF only voltage is applied here to essentially “hold” the ions of a selected m/z
ratio so that they can undergo fragmentation. Fragmentation is carried out using
Ar, N2 or He gas being introduced causing the ions to undergo collision induced
dissociation. The pressure of collision gas can be controlled to provide optimal
fragmentation.
Once the ions have been fragmented, they travel to Q3 which operates as a
second mass filter. The Q3 then scans a range of m/z ratios so as to allow a
range of the fragments produced in Q2 to pass to the detector. This process is
considered MS2 and is referred to as tandem mass spectrometry or MS/MS.
The ions which are selected for in Q3 and subsequently detected are typically
referred to as daughter ions [17].
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Figure 1.16, Quadrapole design
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Figure 1.17, Schematic of a QQQ design
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QQQ-MS/MS is currently the most popular instrument used in the
development of quantitative bioanalytical methods for pharmaceutical analytes.
However, the usefulness and power of this instrument is not limited to the
development of such methods. The strength of this instrument rests in the
generation of daughter ions. The data provided through the m/z ratio of daughter
ions has several applications. First, the m/z ratios can be used to offer an added
degree of specificity to a bioanalytical method. Secondly, the fragmentation
pattern can be looked at like puzzle pieces, put together; they can provide
structural information regarding an unknown compound. Third, the fragmentation
pattern generated can be treated as a fingerprint for identification of complex
biological molecules.
The second mass analyzed to be discussed is an linear ion trap (IT). There
design of the IT is quite similar to the QQQ, in fact the IT also employs a
quadrapole in its design. However, the electronics applied to the quadrapole in
an IT differ from the QQQ.
In an IT mass analyzer, ions generated at the source are accelerated into the
analyzer by a difference in voltage applied across a glass capillary with metal
endcaps. The ions exiting the capillary are focused by a skimmer which has an
electrical charge applied that does not permit ions that fall outside m/z range of
interest to pass to the octapoles, mass filters. The octapoles are designed much
the same as quadrapoles discussed previously, and they act to guide the ions
along the path of the instrument to the ion trap.
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Ion trap
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s
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Figure 1.18, IT-MS
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end caps

The ion trap component of the linear IT mass analyzer is a quadrapole
equipped with electrode end caps on both sides. This component is able to hold
ions within it boundaries due to an RF frequency being applied to the rods of the
quadrapole by the endcapping electrodes. The voltages applied act as gate
doors: opening on one side to allow the entrance and accumulation of ions for
some time; closing and trapping the ions; then re-opening to allow the ions (or
ion fragments) to exit the trap and travel to the detector.
The primary strength of IT mass analyzers is the ability of the trap to hold
a single ion species within the trap, apply a collision gas, and for the ions to
undergo collision induced dissociation. This isolation - collision process, or
tandem MS, can be repeated many times, very rapidly without the need for
multiple analyzers. The fragments, or daughters generated from MSn steps is
extremely valuable for structure elucidation. Another popular analysis made
possible by the data generated in MSn is the identification of proteins using the
fingerprint afforded by the daughter fragments [20].
It is useful to compare the features, or lack of between the QQQ and IT
mass analyzer to summarize their operation and application. Arguably the most
powerful feature of the IT is the ability to conduct multiple isolations and
fragmentations (MSn), whereas, the QQQ is limited to a single fragmentation
(MS2). Further, the ability of the quadrapole of an IT to allow the accumulation of
a specific ion, affords this mass analyzer some advantages in sensitivity. It
should be mentioned that the IT is able to operate under extremely high scan
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speeds which allow it to detect a wider mass range of ions, however, when
operating under such modes, there is a great loss in resolution.
Whereas, the IT has many advantages for providing structural information,
the IT lacks the dynamic or linear range present with QQQ analyzers. While the
trap can hold a large volume of ions, as the number of ions increases, space to
charge dynamics hinder the performance of the analyzer. The excellent dynamic
range afforded by the QQQ, makes it the premier choice for the development of
quantitative bioanalytical methods.

1.5.4

Detectors

The final component of a mass spectrometer is the detector(s). The
detector records either the charge or the current produced when an ion comes
into contact with its surface. There are many types of detectors available, table
V. [20] summarizes the advantages and disadvantages of each type. For this
discussion, the electron multiplier and photomultiplier will be discussed.
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Table V., Characteristics of MS detectors

•Good for checking ion transmission and low sensitivity
measurements

Advantages

Faraday Cup

•Robust
•Long lifetime (>5 years)
•Sensitive (≈gains of 106)

Detector

Photomultiplier Conversion Dynode
(Scintillation Counting)

Disadvantages

•Low amplification (≈10)

•Robust
•Fast response
•Sensitive (≈gains of 106)

•May shorten lifetime of electron multiplier

•Shorter lifetime than scintillation counting
(~3 years)

•Cannot be exposed to light while in
operation

•Increases high mass sensitivity

Electron Multiplier

High Energy Dynodes with electron multiplier

•Reduces resolution
•Expensive

•Limited compatibility with most existing
instruments

•Fast and sensitive

•Detects ions independent of mass and velocity

Array

Charge Detection
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Electron multipliers are comprised of a series of AlO3 dynodes held at increasing
potentials. When an ion strikes the surface, an electron is released. The release
of the first electron causes a chain reaction whereby a great number of electrons
are released at each dynode. This is sometimes referred to as an avalanche
effect. The large volumes of electrodes are collected by an anode, and thus a
signal is recorded. A simple diagram depiction of an electron multipliers is
contained in figure 19.
Photomultipliers are similar in design to electron multipliers in that
electrons bombard a phosphorous screen, as opposed to a dynode. Photos are
released from the phosphorous screen. The photons then encounter a
photocathode screen which results in the release of electrons. The electrons
then travel through the photomultiplier tube which operates as an electron
multiplier, generating a cascade of electrons as discussed previously. There is
one main advantage of a photomultiplier over electron multiplier as the
photomultiplier tube is sealed in a vacuum. The vacuum prevents the detector
from sources of contamination thus increasing the detector lifetime.
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Figure 1.19, Electron multiplier process

61

Figure 1.20, Photomultiplier
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1.6 Conclusion

This chapter has provided an overview of why it is necessary to develop
quantitative bioanalytical methods, the determination of pharmacokinetics and
pharmacodynamics. Further, theory has been introduced regarding the all
components of methods development. A discussion of the extraction of
pharmaceutical analytes from biological matrices has been presented,
highlighting the common procedures used and the theory that dictates their
success. Thereafter, a detailed explanation of the instrumental setup and design
of HPLC was presented. A subsequent discussion of UV detectors followed,
highlighting the usefulness of the detection methods. Finally, the instrumentation
and theory of mass spectrometers was presented. Overall, this chapter should
exhibit the profound understanding of many sophisticated components required
to successfully develop a quantitative analytical method for the determination of
pharmaceutical compounds.
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CHAPTER II

THE DEVELOPMENT OF QUANTITATIVE BIOANALYTICAL
METHODS FOR THE DETERMINATION OF CANNABINOID ANTAGONISTS
RIMONABANT AND SURINABANT

2.1 Introduction to Cannabinoids

2.1.1 Cannabinoid Discovery

Cannabinoids are a class of compounds which are found in the cannabis
plant. Cannabinoids also refer to a broad class of compounds which include:
those structurally related to tetrahydocannabinol (THC); compounds which bind
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to the cannabinoid (CB) receptors; and eicosanoids, which are related to
endocannabinoids.
The discovery of cannabinoids began with the isolation of THC, the primary
psychoactive component of the cannabis plant in 1964 [1]. THC is a compound
which can induce feelings of euphoria, stimulate appetite, and reduce pain [2].
In the body THC is metabolized to 11-hydroxy-THC which continues to
possess psychoactive properties. The metabolite is further oxidized to 11-Nor-9carboxy-THC. Over 100 metabolites of THC have been identified in humans and
animals, but 11-hydroxy-THC and 11-Nor-9-carboxy-THC are the most prevalent.
THC is metabolized in the liver via p450 enzymes and predominantly excreted in
feces (55%) with 20% being excreted in urine [3].
The interesting psychoactive properties of THC have led to it use as a
therapeutic agent in the treatment of both cancer and AIDS due to its analgesic,
appetite stimulating properties. Its success in these treatments has opened the
door to widespread research aiming to elucidate the mechanisms of action of this
exciting class of compounds.
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Figure 2.1, Chemical structure of THC
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2.1.2 Endogenous Cannabinoid System (ECS)

The discovery of THC and the physiological processes it affects has led to the
study of a complex signaling system, termed the endocannabinoid system (ECS).
The endocannabinoid system consists of: cannabinoids, both endogenous and
exogenous; proteins which are involved with the synthesis and inactivation of
cannabinoids; cannabinoid (CB) receptors; and biochemical pathways which are
affected by cannabinoids.
Prior to discussing the ECS, it is necessary to explain normal and retrograde
neurotransmission. In normal neurotransmission, neurotransmitter are released
from the presynaptic neuron, travel across the synaptic cleft, and bind to their
receptor on the postsynaptic neuron.
Cannabinoids, both endogenous and exogenous, participate in retrograde
neurotransmission.

In retrograde neurotransmission (Figure 2.3), the

neurotransmitter (cannabinoid) is released from the postsynaptic neuron and
binds with a receptor on the presynaptic neuron [4].
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Figure 2.2, Normal neurotransmission
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Figure 2.3, Retrograde neurotransmisson
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The exogenous cannabinoid, THC has been discussed. There are also
endogenously produced cannabinoid or endocannabinoids (EC‟s). Two EC‟s
have been identified, anandamide (AEA) and 2-arachidonyl glycerol (2-AG).
Both compounds are metabolites of arachidonic acid [5].
When the ECS is functioning normally, the synthesis of EC‟s is initiated by
membrane depolarization on the postsynaptic neuron which causes an influx of
Ca2+ into the neuron. Ca2+ activates the enzyme transacylase which catalyzes
the first step of synthesis by converting the membrane phospholipid
phosphatidylethanolamine to N-phosphatidylethanolamine (NAPE). In one
proposed mechanism, NAPE is further cleaved to yield the EC, AEA [6].
The EC‟s are highly lipophillic, and are able to cross the cellular membrane of
neurons freely, as opposed to being stored in vesicles, as required for most
neurotransmitters. The synthesis of the EC‟s happens rapidly, when required,
and they are quickly degraded by fatty acid amide hydrolase (FAAH) back to
arachidonic acid plus ethanolamine (AEA) or glycerol (2-AG) [7]. The reaction
scheme for the biosynthesis of EC‟s is presented in figure 2.5.
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Figure 2.4, Chemical structure of AEA and 2-AG

74

Figure 2.5, Biosynthesis of AEA and 2-AG
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Both exogenous cannabinoids and EC act on the CB receptors. CB receptors
are a class of G-protein coupled receptors. G-protein coupled receptors are
seven domain, transmembrane proteins. Transmembrane proteins are affected
by compounds outside of the cell and cause a biochemical response within the
cell.
There are two classes of CB receptors, CB1 and CB2. CB1 receptors are
primarily concentrated in the brain and nervous system. CB2 receptors are
located expressed in the immune system and Hematopoietic stem cells (HSCs).
There is also evidence for CB receptors which do not belong to the CB1 or CB2
subtypes [8], however, there is little understood about these receptors.
It has been reported that the CB1 receptor is the most widely expressed
receptor in the brain [9]. A diagram which depicts the areas of the brain where
the CB1 receptor is expressed is contained in figure 2.7 [9]. When the CB1
receptor is activated by cannabinoids, it is though to cause neuronal membrane
depolarization which causes a reduction in GABA neurotransmission. The CB1
receptor is also expressed in other tissues, notably the liver, where its activation
stimulates lipogenesis [10].
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Figure 2.6, Protein structure of the CB1 receptor [8]
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Figure 2.7, Areas of the brain with CB1 receptor expression
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As previously mentioned, the CB2 receptor is expressed predominantly in
immune cells, suggest a role in the function of the immune system. Research
on the CB2 receptor has shown that it may affect macrophage-mediated helper T
cell activation [11].

Although some CB2 receptors have been isolated from

brain tissue, the role of this receptor in the nervous system is not well studied.
Cannabinoid binding to the CB receptor causes a wide range of biochemical
responses. The activation of CB1 receptors causes the inhibition of cyclic
adenosine monophosphate (cAMP), a secondary messenger involved in
transferring the signal of many extracellular molecules [12]. Further CB1
activation causes an inhibition of voltage activated Ca2+ channels and activates
inwardly rectifying K+ channels. The inhibition of Ca2+ combined with the
activation of K+ together inhibits the release of neurotransmitters [13]. Finally CB
activation has to increase the activity of mitogen activated protein kinase (MAPK)
which affects several gene transcription factors including c-Fos and Krox-24 [14].
In addition to the biochemical processes which cannabinoids affect, there are
several behavioral or physiological consequences to CB receptor activation.
These processes include, but are not limited to: feeding response; energy
balance and metabolism; pain perception; and memory, learning and emotion [5].
As evidenced in figure 2.7, CB1 receptors are highly expressed in the
hypothalamus and dopamine reward regions of the brain. These brain regions
are known to affect food intake, energy balance and reward systems. Therefore,
cannabinoids and the modulation of the ECS is the subject of strong investigation
for its potential role in the treatment of obesity and drug addiction.
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2.1.3 Cannabinoid Antagonists
As discussed in the previous section, cannabinoids, particularly EC‟s are
fervently being investigated to understand how their modulation can be used to
treat several conditions. One facet of this investigation revolves around
compounds which act to inhibit the biochemical and physiological response to
EC‟s.
The rationale of blocking the cannabinoids from binding to the CB receptor
has shown to have two principle therapeutic outlooks; the treatment of obesity
and metabolic disorders, and as a treatment for addiction to drugs of abuse.
Studies show that by blocking EC‟s, there is a reduction in food intake. Further,
when the CB1 receptor is not activated, there is effect on metabolism, causing
the body to use energy more efficiently. Finally, lipogenesis, the generation of fat
cells is slowed by the inhibition of CB receptors.
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Figure 2.8, Overview of the affect of the ECS on food intake, energy storage
and balance
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The biological responses caused by the blocking the activation of CB
receptors that implicate this process as a potential treatment for drug abuse are
related to the neurotransmitter, dopamine and the dopamine dependant
mesolimbic reward system [15]. As described previously, the binding of EC‟s has
an effect on ion transport in the central nervous system which inhibits the normal
release of neurotransmitters, including dopamine. The release of dopamine
causes a general sense of well being and is required for an animal to function
normally. By blocking the EC‟s from their site of action, the release of dopamine
is restored.
The second facet of the rationale for inhibiting CB receptors to treat drug
addiction involves the mesolimbic reward system. The release of dopamine
affects the brains reward system by essentially reinforcing certain behaviors. It is
accepted that this reward system participates is the biological basis of drug
addiction. Though not well understood, it is suggested that blocking the EC‟s
from binding permits a modulation of the brains reward system and thus, may
have promise as a treatment for drug addiction.
The compounds which inhibit the CB receptors are often referred to as
cannabinoid or endocannabinoid antagonists, or inverse agonists [16]. For
clarity, several terms should be defined: agonist, a molecule which stimulates a
cellular response by inducing a conformational change in the receptor;
antagonist, a compound which is unable to cause the conformational change
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required to stimulate a cellular response; and inverse agonist, which causes a
stabilization of the receptors conformation and causes a response inverse to that
of the agonist.
It is possible to further describe the different type of receptor binding using a
two state model. In this model, receptors are either active or inactive. Agonists
bind to receptors that are in the active state and have a stimulatory effect.
Antagonists can bind to a receptor in either the active or inactive state. Inverse
agonists only bind to the inactive state of a receptor, causing an inhibitory effect.
There is evidence that the CB inhibitors discussed in the next sections act as
both inverse agonists, as well as antagonists. In vitro, at clinically relevant
doses, these compounds act as antagonists; but at higher doses, behave as
inverse agonists [16]. It is not currently known the type of inhibition that is
caused in vivo. For purposes of consistency and clarity, all references to
compounds which inhibit CB receptors will be referred to as antagonists.

2.1.4 Rimonabant

Rimonabant [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4-methyl-1 H-pyrazole-3-carboxamidehydrochloride)], the first selective CB1
receptor antagonist was discovered in 1994 [17]. The chemical structure of
rimonabant is contained in figure 2.9. Rimonabant has been shown to be orally
active. Further, administration of rimonabant is ably to fully antagonize the
effects of the CB receptor agonist, THC.
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Figure 2.9, Chemical structure of rimonabant
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Rimonabant has been investigated as a therapeutic agent for the
treatment of both obesity and drug addiction. The administration of rimonabant
to rodents has shown to reduce the rewarding/reinforcing behaviors of several
drugs of abuse including heroin [18], cocaine [19], nicotine [20] and alcohol [21].
Further, there is evidence that rodents administered this drug show a marked
decrease in food consumption [22] .
Rimonabant has been investigated in a phase II clinical trial to be used in the
treatment of alcoholism [23], a phase III clinical trial for treatment of diabetes [24]
and a phase III clinical trial for treatment of obesity [25].

In 2006, rimonabant

was approved under the brand name Acomplia by the European Union as an
over-the-counter medication. In October of 2008, the European Medicines
Agency (EMEA) recommended that the use of Acomplia be suspended [26]. In
November of 2008, the manufacturer of Acomplia, Sanofi Aventis, discontinued
production of the drug. The reasons that Acomplia has been abandoned as a
therapy relate to unwanted neurological side effects, particularly depression. It
has been stated that patients taking Acomplia have twice the risk of developing
depression than those taking placebo [27].
Despite rimonabant being removed from the drug pipeline, there continues to
be a strong interest in its molecular modes of action and the behavioral
responses which are generated. In fact, in the first half of 2009 over 50
publications have been generated further investigating this drug. Further, many
publications are the result of animal behavior studies.
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One of the aims of this work is to present the development of a quantitative
bioanalytical method, using HPLC-MS/MS, for the determination of rimonabant
in biological samples. Prior to the development of the method discussed in the
next sections, no method was publicly available. This method is able to measure
rimonabant in human, rat and canine plasma; as well as, in rat brain tissue. The
method developed has been applied to the measurement of rimonabant in two
separate animal studies. Further, the method can be applied to future clinical
and toxicological studies to establish pharmacokinetic and phamacodynamic
profiles in various animal models. This work will remains a valuable resource to
the research community as a better understanding of the ECS and the
compounds which modulate it, emerges.

2.1.5 Surinabant

Surinabant [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1piperidinyl)-1H-pyrazole-3-carboxamide] is an CB receptor antagonist, which was
developed by Sanofi Aventis [28]. The chemical structure of surinabant is
contained in figure 2.10.
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Figure 2.10, Chemical structure of surinabant
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Surinabant is a second-generation CB receptor antagonist. It has a longer
duration of action than the rimonabant, and enhanced oral activity [29] [30] [31].
Further, surinabant may have advantages over rimonabant in that it is reported
that surinabant has both a higher affinity for CB receptors in the brain and has up
to three times longer occupancy in the brain [32].
Surinabant differs structurally from rimonabant in that it has an ethyl group
attached to the central nitrogen ring versus a methyl group in this position on
rimonabant. It has been suggested that the enhanced biological effects of
surinabant are due to its slightly larger hydrophobicity. Greater hydrophobicity
has two main effects, it is able to cross the blood brain barrier more rapidly; and it
may move more easily across the through the membrane of post synaptic
neuronal cells.
Surinabant has been in clinical trials in Europe for treatment of both obesity
[33] and nicotine addition [34]. Current research using surinabant elucidates a
relationship between nicotine, metabolism and weight gain [35]. It has further
been investigated for the treatment of alcoholism and attention deficit
hyperactivity disorder (ADHD). Evidence for the potential of surinabant in the
treatment of alcoholism is shown in a study that describes the administration of
surinabant is able to reduce both voluntary ethanol consumption as well as
alcohol intake [13].
Clinical trials have been completed, and this compound has been removed
from the drug pipeline of Sanofi Aventis. Despite the noticeable abandonment of
this compound, there is a great deal that remains unknown about the ECS. The
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method developed for the determination of rimonabant was quickly responded to
with enthusiasm by the research community. It is logical that a method that can
measure a compound which varies only slightly in chemical structure, yet has
markedly increased biological responses; would be a valuable tool for the
scientific community.
The work described here will outline the development both an HPLC-UV and
an HPLC-MS/MS quantitative bioanalytical method, for the determination of
surinabant in biological matrices. Prior to the publication of this work, no method
was publicly available to measure the concentration of surinabant in any
biological matrix.

2.1.6 Conclusion

The endocannabinoid system (ECS) is a complex signaling system that
affects several biological events including; regulating energy balance and
behaviors such as food intake, fear and anxiety. As previously discussed, ECs
are biochemically involved in many physiological processes, including food intake
and addiction. Naturally, compounds which are able to modulate, via agonism or
antagonism, the ECS are of great interest.
The work presented in this chapter will describe quantitative, bioanalytical
methods that can be used to measure the concentration of the CB receptor
antagonists, rimonabant and surinabant. These methods have been applied to
animal studies. To date, the data obtained from the use of these methods has
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aided researchers in the fields of psychiatry and metabolic disorders to further
understand and interpret their experimental results. The future applications of
these methods cannot be predicted; however, the value to science is clearly of
great value.

2.2 Development of a Quantitative Bioanalytical Method for the
Determination of Rimonabant

2.2.1 Introduction

Prior to the development of the method presented in this section, there
was no publicly available method to measure the concentration of rimonabant
in biological samples. A HPLC-MS/MS method was developed and validated
using a human plasma matrix. In addition to human plasma, successful
measurement of rimonabant was achieved in the following matrices: rat
plasma, rat brain and canine plasma. For this work validation was conducted
to demonstrate the robustness and reproducibility of the method. All
validation parameters followed the guidelines contained in the document, U.S.
Food and Drug Administration Bioanalytical Method Development – Guidance
for Industry [36]
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2.2.2 Materials and Methods

Reagents

Acetic acid, HPLC-grade acetonitrile, dimethyl sulfoxide (DMSO), formic acid,
and 1- (2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1Hpyrazole-3-carboxamidetrifluoroacetate salt (AM251, the internal standard for this
study), Cremophor EL, and Tween 80 were purchase from Sigma-Aldrich (St.
Louis, MO, USA). Rimonabant, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide was provided, at no cost, by
National Institute of Mental Health (Bethesda, MD, USA) Drug Repository (NIMH
code 5S-705.) Dr. Michael Kalafatis at Cleveland State University, graciously
donated pooled human plasma was from Haemtech, Inc (Essex Junction,
Vermont, USA).
The rimonabant (C22H21Cl3N4O) stock solution (1.00 mg/ml) was prepared by
weighing1.12 mg of the compound into a 1.5 ml Eppendorf tube (Eppendorf,
Westbury, NY, USA) and dissolving it with 1.12ml of DMSO. A stock solution
(1.00 mg/ml) of AM251 trifluoroacetate salt (C22H21N4OCl2I · C2HF3O2) was
prepared by weighing 1.24 mg of the compound into a 1.5 mL Eppendorf tube
and dissolving it with 1.24 ml of DMSO.
Once the compounds were dissolved in DMSO, both rimonabant and AM251
stock solutions were transferred to 1.5 ml amber glass autosampler vials, sealed
with parafilm, and were stored at - 20 ºC when not in use. A rimonabant working
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solution (100 μg/ml) was prepared by a dilution (1/10) of the rimonabant stock
solution with DMSO. A working solution (2.00 μg/ml) of AM251 was prepared by
a three-step dilution (1/8.3, 1/10, 1/5) of the AM251 trifluoroacetate salt stock
solution with DMSO. A mobile phase for liquid chromatographic separation was
prepared by first adding formic acid (HCOOH) to water. The formic acid/H2O
solution was mixed with acetonitrile (50:50 v/v) with the HCOOH concentration
being 0.1% of the final mobile phase volume. All solutions were stored at 4◦C
when not in use.

Calibrators and Controls

Pooled human, Sprague-Dawley rat and mixed breed canine plasmas which
contained no detectable rimonabant were used as the blank plasmas to prepare
human and rat plasma calibrators and controls for this study. Standard solutions
of rimonabant (0.0100, 0.0200, 0.100, 0.150, 0.200, 1.00, 1.50, 2.00, 10.0,15.0,
20.0 μg/ml) were prepared by a serial dilution of the working solution (100 μg/ml)
with DMSO. Plasma calibrators of rimonabant (0.500, 1.00, 5.00, 10.0, 50.0, 100,
500, 1.00 x 103 ng/ml) were prepared by a 1:20 dilution of the corresponding
rimonabant standard solutions with the blank plasma. A 1:20 dilution of the
corresponding rimonabant standard solutions with the blank plasma was
conducted to prepare the rimonabant plasma controls (7.50, 75.0, 750 ng/ml). All
plasma samples were stored at – 20◦C when not in use.
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Protein Precipitation

Rimonabant was extracted from plasma samples using the following protocol:
First, 200 μl of plasma sample was pipetted into a 1.5 ml Eppendorf tube;
thereafter, 10.0 μl of the AM251 working solution (2.00 μg/ml) and 50.0 μl of
acetic acid were added to the mixture. The mixture was vortex mixed and 1.00 ml
of acetonitrile was added. The ACN/plasma solution was then vortexed again
subsequently centrifuged for 15 minutes at 13,000 g. The supernatant present
after centrifugation was transferred to a 1.5 ml Eppendorf tube, and evaporated
to dryness in a DNA 120 SpeedVac® (ThermoSavant, Hollbrook, NY, USA) at 65
ºC for 90 min. The sample was reconstituted in 200 μl of the mobile phase prior
to analysis.

Rimonabant Recovery

The ability of the protein precipitation procedure to recover rimonabant by
was measured using rimonabant plasma controls and rimonabant reference
solutions at three different concentrations (7.50, 75.0, 750 ng/ml). The reference
solutions contained the same matrix as that of plasma controls, which were
prepared using blank plasma as samples by the same extraction procedure as
that of plasma controls, and reconstituted in the mobile phase with corresponding
rimonabant concentrations.
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Animal Samples (rat)

Sprague-Dawley rats (Taconic Farms) were bred in the vivarium of
Binghamton University. On postnatal (P) day 1, litters were chosen with 7-10
subjects, whenever possible retaining six males and four females. Animals were
weaned on P21, housed in same-sex pairs and maintained on a 14/10 hour
light/dark cycle (lights on at 7 am) with food and water available ad libitum. All
experimental procedures were approved by the Institutional Animal Care and
Use Committee at Binghamton University. The animals were an average 70
days old. The average body weight of the animals was 300 grams. Rimonabant
was delivered as a suspension of 2.0% Cremaphor EL, 0.1% Tween 80 and
deionized water. Intraperitonal (i.p.) injections of 10 mg/kg in a volume of 5 ml
were administered. The animals were decapitated at 30 minutes and 12 hours.
Trunk blood samples were obtained by allowing the blood to freely drain into
centrifuge tubes. An average of 3 mL of blood was collected from each animal in
tubes containing 0.1 ml of 0.1 M EDTA. High-speed centrifugation was used to
separate the plasma from whole blood. Plasma was stored at - 80 ºC until
analysis.

Animal Samples (canine)

Mixed breed canine plasma collected using lithium/heparin (Li-Hep) as an
anticoagulant was purchased from Lampire Biological Laboratories (Pipersville,
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PA, USA). Dr. Joyce Richey at the University of Southern California, Keck
School of Medicine provided the canine samples to be analyzed. The plasma
was collected in Li-Hep coated test tubes and EDTA was added to the plasma.
No further information regarding the breeding or dosing of animals, nor the
collection or storage of plasma was provided.

Instrumental Setup

The instrumental setup used in this work consisted of an HP1100 pump by
Hewlett Packard (Palo Alto, CA, USA), an HP1100 autosampler, a stainless steel
in-line filter (0.5 μm pore, 0.23 μl dead volume) by Upchurch Scientific (Oak
Harbor, WA, USA), a YMCTM Pro C4 cartridge column (3 μm, 120 Å, 2.0 mm x
50 mm) by Waters (Milford, MA, USA), a stainless steel splitting tee (1/16” x 0.25
mm) by Valco (Houston, TX, USA), and a Quattro II triple quadrupole mass
spectrometer by Micromass (Manchester, UK). All fluidic connections in the
system were made using high-pressure polyether ether ketone (PEEK) tubing
(0.0625 in. o.d., 0.0100 in. i.d.). The post-column split ratio was 1:2 with a smaller
flow (ca. 63 μl/min) to the MS detector and the larger one to the waste.

HPLC Separation

Analytical separation was performed via a Waters YMCTM Pro C4 cartridge
column. Before analysis, the cartridge column was equilibrated with mobile
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phase at a flow rate of 0.200 ml/min for about 15 min. During the analyses, 20 μl
of sample was injected by the autosampler and carried onto the cartridge column
by the mobile phase at a flow rate of 0.200 ml/min. Rimonabant and AM251
(internal standard) were separated from the sample matrix with retention times of
6.8 and 7.8 min, respectively. The total run time was 10.0 min per sample.

MS Detector Settings

Electrospray ionization mode (ESI+) was utilized on the Micromass Quattro II
triple quadrupole mass spectrometer. Tuning of the mass spectrometer was
achieved by infusion of a mixture of rimonabant (1.0 μg/ml) and AM251 (1.0
μg/ml) in the mobile phase at a flow rate of 3.0 μl/min with a syringe pump
(Harvard Apparatus, South Natick, MA, USA). Optimal ionization conditions were
as follows: nitrogen sheath and desolvation gas at 10 and 350 l/h, capillary at 3.5
kV, HV lens at 0.5 kV, cone at 40 V, skimmer at 1.5 V, RF lens at 0.2 V, ion
source temperature at 95◦C, ion energy at 1.0 V, low- and high-mass resolution
at 15, and multiplier at 700 V. Full-scan spectra were acquired in the continuum
mode at a scan rate 400 u/s. The instrument was operated in multiple reaction
monitoring (MRM) mode for quantitation, which was set as follows: m/z 463 →
363 for rimonabant, m/z 555 → 455 for AM251, argon collision gas at 2.0-2.5
μbar, cone at 40 V, collision energy at 20 V for both analytes, low- and high-mass
resolution at 10 for quadrupole 1 and 15 for quadrupole 3, dwell time at 0.1 s,
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and the inter-scan delay at 0.01 s. The parameters for ionization remained the
same as previously discussed.

Analysis of Data

Data acquisition and peak integration were performed using the Micromass
Masslynx software (version 3.4). The peak area ratios of rimonabant plasma
calibrators to the internal standard were plotted against plasma rimonabant
concentrations for a regression equation. Rimonabant concentration of an
unknown plasma sample was determined by the regression equation after
obtaining the peak area ratio of rimonabant in the unknown to the internal
standard from the mass chromatogram.

2.2.3 Results and Discussion

Selection of Solvent for Stocks, Plasma Calibrators and Controls

Rimonabant and AM251 are caboxamide derivatives which are not
water soluble. In many situations, the addition of acid to a solution will protonate
the compound and, due to ionization, improve its water solubility. In this work
0.1M hydrochloric acid (HCl) was added to the solution which was not able to
sufficiently aid in the solubility.
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Due to the hydrophobicity of these compounds, it was not possible to dissolve
them directly into plasma and a suitable stock solution solvent was required.
Both compounds were easily dissolved in both acetonitrile (ACN) and methanol
(MeOH). However, it has been established that when these solvents are used to
prepare stock solutions, the subsequent addition to plasma can cause protein
precipitation, in amounts less than 1% [37]. Protein precipitation may result in
poor precision of the analytical method.
DMSO was investigated as a potential alternative to ACN and MeOH. Both
rimonabant and AM251 were readily soluble in DMSO, and up to a 25% addition
of DMSO to plasma did not result in appreciable protein precipitation. Therefore,
DMSO was selected as the solvent for all stock and working solutions. In order
to assure that no precipitation would occur, DMSO was limited to 10% v/v in all
plasma controls and calibrators.

Extraction of Analyte and Recovery

As described in section 1.2, the first step in bioanalytical method
development is the extraction of the analyte from the biological matrix which it
exists in. In the case of rimonabant, on-line sample extraction was first
considered. On-line sample extraction is solid phase extraction (SPE) conducted
“on-line”, or in the automated set-up of the instrumental procedure. SPE is
discussed in detail in section 1.2.4.
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The automated nature of on-line SPE provides several advantages over SPE:
cost, the column used for extraction is reused, up to hundreds of times; precision,
there is no pipetting involved in sample loading which reduces human error; and
time, the automation of the process allows for much faster extractions than that
of SPE. Unfortunately, the hydrophobic nature of rimonabant caused a
significant carryover of sample between injections, and thus on-line extraction
was abandoned.
Since on-line extraction was not possible, a protein precipitation protocol was
developed. The protein precipitation utilized 100% ACN, as the extraction
solvent. Prior to the addition of ACN, acetic acid was added to the plasma. The
addition of acid protonates the plasma proteins, which can serve to reduce the
binding of drug with plasma proteins. Further, protonation disrupts the hydration
layer of proteins in solution as discussed in section 1.2.3. This disruption can
reduce the aggregation of proteins which can lead to poor reproducibility and
recovery.
The recovery of rimonabant was ascertained at three concentrations, low (7.5
ng/mL), middle (75.0 ng/mL) and high (750 ng/mL). Recovery describes the
difference between the mean peak area ratio of the signal of rimonabant
obtained from samples which were spiked with rimonabant prior to the protein
precipitation, to the signals obtained from samples spiked with rimonabant after
the protein precipitation. Both absolute recovery, the recovery of rimonabant
alone; and relative recovery, the internal standard corrected recovery was
calculated.
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Figure 2.11, Benefit to using DMSO and acetic acid in protein precipitation
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According the FDA‟s guidance for the industry, there is no absolute value for
recovery required. It is only necessary that the recovery be consistent and
reproducible across the concentration range of interest. The absolute and
relative recoveries of rimonabant from the human plasma matrix are contained in
Table V.
The recovery of rimonabant in canine plasma was verified at the low,
medium and high concentrations described above and were determined to be:
89.8%, 89.4% and 91.7 %, respectively. As clearly indicated by table V
combined with the values obtained using canine plasma, the protein precipitation
protocol is suitable for the extraction of rimonabant from these matrices.
It is worth mentioning that the use of 70% ACN as the extraction solvent was
investigated. The rationale for using a lower amount of ACN was an attempt to
reduce cost due to solvent consumption. The reduced ACN resulted in lower
extraction efficiency. The poor recovery can be attributed to a change in the
partitioning of the compounds when a lower amount of ACN was used, as
discussed in section 1.2.2.
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Table VI, Recovery of rimonabant in human plasma

Absolute and relative recoveries of rimonabant and AM251 in human plasma
Compound

7.50 ng/ml
Recovery (%)

CV (%)

75.0 ng/ml

750 ng/ml

Recovery (%) CV (%) Recovery (%) CV (%)

SR141716

83.0

2

83.7

4

85.1

5

AM251

87.3

3

91.0

4

85.8

4

SR141716/AM251

95.2

3

92.0

0.6

99.2

1

The number of measurements was 3 for each datum point.
The concentration of the internal standard AM251 was 100 ng/ml.
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HPLC Separation

Although neither the MS detector, nor the application of the method,
required that rimonabant and AM251 be chromatographically separated; this
achievement would result in better method sensitivity. Therefore, several
analytical columns and mobile phase compositions were tested to first, achieve
baseline separation and secondly, assure that the retention times were not
inhibitorily long.
The first conditions tested used a Waters YMC™Pro C18 column (3 μm, 120
A°, 2.0mm×50 mm) and a mobile phase containing 90% CH3OH/0.1% HCOOH in
water, rimonabant and the AM251 were co-eluted at retention times of 2.5 and
2.8 min. Next a mobile phase of 70% CH3CN/0.1% HCOOH in water, it was
possible to achieve baseline separation of rimonabant and the internal standard
with retention times of 4.6 and 5.6 min on the Waters YMC™ Pro C18 cartridge.
As discussed in section 1.1, a good bioanalytical method will aim to keep
the cost as low as reasonable. Therefore, in an effort to reduce the amount of
ACN in the mobile phase, a Waters YMC™ Pro C8 cartridge column (3 μm, 120
Å, 2.0 mm x 50 mm) was tested. With the mobile phase composition of 50%
CH3CN/0.1% HCOOH in water, rimonabant and AM251 were partially separated
at 13.5 and 17.0 min.
Again, it is desirable to maintain a short analysis time so, to reduce the
separation time, a Waters YMC™ Pro C4 cartridge column (3 μm, 120 Å, 2.0 mm
x 50 mm) and a mobile phase composition of 50% CH3CN/0.1% HCOOH in
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water were used. This column and mobile phase system allowed for separation
of rimonabant and AM251 with retention times of 6.8 and 7.8 min. Therefore, a
Waters YMC™ Pro C4 cartridge column and a mobile phase composition of 50%
CH3CN/0.1% HCOOH in water were utilized for the subsequent analytical
separations. Representative mass chromatograms of rimonabant and AM251
using this chromatographic systems are contained in figure 2.12.
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AM251

rimonabant

AM251

rimonabant

AM251

rimonabant

Figure 2.12, Representative mass chromatograms of rimonabant and AM251
in (A) untreated blank plasma, (B) plasma treated with rimonabant only, and
(C) plasma treated with 100 μL of both rimonabant and AM251
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MS Detection

Section 1.5 describes the theory of mass spectrometry detectors, indicating
that the mass to charge or m/z ratio of ions is detected. Most modern instrument
are capable of analyzing: positive ions, i.e. the molecular weight of the analyte
plus a proton or M+H+; negative ions, i.e. the molecular weight of the analyte
minus a proton or M -H+; or alternating between positive and negative ion
detection.
This work used the MS instrument in multiple reaction monitoring mode
(MRM). This is a feature of most sophisticated instruments in use today. In
MRM mode, the detector is able to operate and record data for multiple analytes
simultaneously. Therefore, the signal for the analyte and internal standard can
be extracted from the total ion signal during the data processing step.
Based on the chemical structures of rimonabant and AM251, they will more
easily undergo protonation than deprotonation, therefore positive electrospray
ionization mode was employed for their detection. The full-scan spectra showed
that rimonabant produced a predominant quasi-molecular ion at m/z 463 and
AM251 at an m/z of 555. Therefore, these ions were chosen as parent ions for
fragmentation in the MRM mode.
The daughter spectra of the parent ions revealed that the predominant
daughter fragments were at m/z 363 for rimonabant and m/z 455 for AM251.
These daughter ions were chosen for analyte quantitation. The full scan and
daughter fragmentation spectra are contained in figure 2.13.
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(A) rimonabant

(B) AM251

(C) rimonabant
daughter ions

(C) AM251
daughter ions

Figure 2.13, Full scan spectra of (A) rimonabant, (B) AM251; daughter
spectra of (C) rimonabant and (D) AM251
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The use of MRM mode for detection of rimonabant and AM251 offered
suitable specificity, which is exhibited by the lack of interference from any
compounds in the blank plasma, as demonstrated in figure 2.12.
The fragmentation scheme for rimonabant and AM251 can be proposed
based upon the fact that the predominant daughter ions were 100 amu less than
their parent ions.
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Figure 2.14, Proposed fragmentation scheme for rimonabant (SR141716) and
AM251
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Method Validation (Linearity, Detection Limits, Precision, Accuracy and
Stability)

Via Human Plasma for Rat Study

As described in section 2.2.2 the volume of rat plasma obtained from each
animal was limited to 3.0 mL. Several validation parameters were tested to
assure that the difference in matrix had no appreciable affect on the validation.
Therefore, due to the limited supply of blank rat plasma this method was
validated using blank human plasma.
The linearity of the response of the detector was determined by the peak
area ratios of rimonabant to the internal standard and plotted versus the
concentration of plasma calibrators. This method has a linear range of 5.00 –
1000 ng/mL with a correlation coefficient of 0.999. The mean calibration
equation, determined from three separate calibration curves over a 6 month
period was y = 0.0196x.
The guidelines prescribed by the FDA industry guidelines sets forth several
values for acceptable detection limits, precision, accuracy and stability. These
values require that the limit of detection (LOD) and limit of quantitation (LOQ)
must be 3 and 10 times the signal to noise, respectively. The calculated LOD
and LOQ for this method (based on 5 replicates) are 1.09 and 3.62 ng/mL,
respectively.
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The precise detection of all samples should be accomplished with less than
15% (20% at the lowest concentration) error to ensure the reproducibility of the
entire method. The intra-assay precision, or the precision afforded by the mass
spectrometer was determined for this method. Additionally, the inter-assay
precision from sample to sample, an indication of the human precision of the
method was also determined. All precision values are reported as %CV which is
calculated by dividing the standard deviation by the mean value and multiplying
by 100.

The precision values calculated are contained in table VI. All values

reported are internal standard corrected.
The accuracy, which is determined by the relationship of the measured
concentration of analyte to the real concentration, should also be within 15%.
The equation used to calculate accuracy is contained in equation 2.1.

[[(real concentration – measured concentration) / real concentration] x 100]

(2.1)

The accuracy of this method was ascertained at 7.5, 75.0 and 750 ng/mL and
was found to be 105, 99.5 and 100% respectively. These values fall within the
15-20% error window suggested in the FDA guidelines.
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Table VII, Intra-and inter-assay precision of rimonabant measurement

Intra- and inter-assay precision of rimonabant in human plasma
CV (%)
[SR141716] (ng/ml)

Intra-run

Inter-run

7.50

0.9

6

75.0

1

0.5

750

0.4

2

The concentration of the internal standard AM251 was 100 ng/ml.
The number of measurements was 3 for each datum point.
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Finally, it is important to determine the stability of the analyte under
conditions anticipated to be appropriate for the methods application. In this
method, the freeze/thaw (3 cycles; -20◦ → room temperature), and short term
mobile phase (stock) and plasma (calibrator) stability was ascertained. Error was
measured as the difference in signal obtained from the analyte after subjecting
the samples to the condition to the signal of the analyte at time zero. The
stability was investigated at both low and high concentrations.

Under the

conditions studied, the error ranged from 6.6 to 8.9%, which indicates that
rimonabant is stable under these circumstances.

Canine Plasma

Before being applied to the canine plasma samples the accuracy and
precision of the developed method was checked to assure the transfer of the
method to this new matrix. The %CV, representing precision ranged from 110.3%, well within the permitted range. Further the accuracy ranged from 85.7 to
97.4%, indicating the method could accurately measure the concentration of
rimonabant.
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Rat Plasma Analysis

The validated method was used to measure rimonabant in plasma samples
from rats after intraperitoneal injection of rimonabant at the dose of 10 mg/kg. In
the analyses, the frozen rat plasma samples and blank plasma were thawed to
room temperature, 200 μl of plasma samples together with the blank plasma
were prepared by the protein precipitation procedure described in Section 2.2.2
and analyzed by the LC-MS-MS method.
While there was no interference found in the untreated rat plasma (Figure
2.15A), rimonabant was detected in rat plasma after both the 30 min and 12 h
injection (Figures 2.15B and 2.15C). Although the dose and the sampling times
were not optimized to establish a pharmacokinetic study of this drug in the, the
results demonstrate the applicability of the method for the measurement of
rimonabant in plasma samples. Furthermore, the plasma concentration at 12 h
after injection was higher than that at 30 min. This finding was consistent with the
pharmacokinetic data in the US FDA briefing document (NDA 21-888, June 13,
2007), which showed a mean half-life of ca. 16 days for the drug in humans.
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Figure 2.15, Mass chromatogram of (A) blank plasma, (B) animal treated for
30 minutes, (C) animal treated for 12 hours and (D) the low calibrator (5
ng/mL)
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Rat Brain Tissue Analysis

This method, though not validated for the brain tissue matrix, was
introductorily applied to samples. In this analysis, the water in a volume of ten 5
mL/gram of brain tissue was added to the whole rat brains. The brain/water
mixture was homogenized with an immersion blended. Thereafter, 200 μL of the
homogenized tissue solution was pipetted into centrifuge tubes, an amount of
rimonabant calibration standard was added and the protein precipitation
procedure described in section 2.2.2 was conducted. Figure 2.16 shows a
representative mass chromatogram for rimonabant extracted from a brain tissue
solution. As evidenced in figure 2.16, rimonabant is clearly detectable when
extracted from brain tissue. No further investigation into the extraction, detection
or validation of this method for the measurement of rimonabant in the brain
matrix was conducted
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Figure 2.16, Representative mass chromatogram of rimonabant extracted
from brain tissue
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.

Canine Plasma Analysis

The canine samples, together with calibrators and controls were prepared
as described in section 2.2.2. As mentioned previously, there was no information
provided regarding the dosing and time points for these samples. Based on the
lack of information provided, it is not possible to discuss the measurement of
rimonabant in these samples. However, the ability of the LC-MS-MS method to
detect rimonabant in all samples which was expected to be found, speaks to the
validity and applicability of this method in the research community. The range of
rimonabant concentrations detected in this study were from 20-125 ng/mL A
representative chromatogram of the low and high end of the concentrations
detected, as well as the calibrator in this range, is contained in figure 2.17.
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Figure 2.17, Representative mass chromatograms of rimonabant extracted
from canine plasma with calculated concentrations of (A) 112 ng/mL, (B) 21
ng/mL and (C) 100 ng/mL calibrator
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2.2.4 Conclusion

A rapid, sensitive HPLC-MS-MS bioanalytical method has been developed
and validated for the measurement of rimonabant. This method is able to
effectively extract rimonabant from the matrices with suitable precision and
recovery. Further, the mass spectrometric detection of rimonabant enables an
accurate measurement of analyte concentration. Finally, the method has been
successfully applied to a wide range of biological matrices, including, human
plasma, rat plasma, rat brain tissue and canine plasma. This method can be
used in future pharmacokinetic and phamacodynamic studies.

2.3 Development of a Quantitative Bioanalytical Method for the
Measurement of Surinabant

2.3.1 Introduction

The development of the bioanalytical method to measure rimonabant was met
with strong enthusiasm in the research community [38]. Within months of the
manuscript being published, our research group was approached to conduct the
analysis of a large scale animal study. During this time, there was promising
interest in the structurally similar CB antagonist, surinabant, as a therapeutic
agent. Due to the structural similarities of the compounds, it was expected that
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the quantitative analytical method developed for rimonabant could be applied to
the measurement of surinabant.
Further, the results of the rimonabant canine study indicated that clinically
relevant concentrations of the drug were in the 20-125 ng/mL range. This
concentration range suggested that there are a wide range of studies which find
prove useful with a method employing a UV detector. UV detectors are much
less expensive, more widely available and easy to operate than a mass
spectrometer. Thus, a quantitative bioanalytical method using a UV detector was
development for the measurement of surinabant.

2.3.2 Materials and Methods

Reagents

Acetic acid, HPLC-grade acetonitrile, dimethyl sulfoxide (DMSO), formic acid,
and 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1Hpyrazole-3-carboxamide trifluoroacetate salt (AM251) were from Sigma-Aldrich
(St. Louis, MO, USA). Surinabant, (5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)4-ethyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide), was obtained from the drug
repository (NIMH code S-908) of National Institute of Mental Health (Bethesda,
MD, USA). Pooled human plasma which contained no detectable surinabant
was from Haemtech, Inc (Essex Junction, Vermont, USA).
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A stock solution (1.00 mg/ml) of surinabant (C23H24Cl2N4BrO) was prepared
by weighing 1.32 mg of the compound into a 1.5 ml Eppendorf tube (Eppendorf,
Westbury, NY, USA) and thereafter, it was dissolved with 1.32 ml of DMSO. A
stock solution (1.00 mg/ml) of AM251 trifluoroacetate salt
C22H21N4OCl2I·C2HF3O2) was prepared by weighing 1.18 mg of the compound
into a 1.5 ml Eppendorf tube and dissolving it with 1.18 ml of DMSO. Once the
compounds had been dissolved in DMSO, both surinabant and AM251 stock
solutions were transferred to 1.5 ml amber glass vials and stored at - 20 ºC when
not in use.
A working solution (100 μg/ml) of surinabant was prepared by a dilution
(1/10) of the surinabant stock solution with DMSO. A working solution (5.00
μg/ml) of AM251 was prepared by a three-step dilution (1/8.3, 1/10, 1/2) of the
AM251 trifluoroacetate salt stock solution with DMSO. A mobile phase for liquid
chromatographic separation was prepared by mixing 99.9% CH3OH/H2O (50:50,
v/v) and 0.1% HCOOH. The above solutions were stored at 4 C when not in
use.

Calibrators and Controls

Pooled human plasma containing no detectable surinabant was used as the
blank plasma to prepare human plasma calibrators and controls for this study.
Surinabant standard solutions (0.100, 0.1500, 0.200, 1.00, 1.50, 2.00, 5.00, 10.0,
15.0, 20.0 and 30.0 μg/ml) were prepared by a serial dilution of the working
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solution (100 μg/ml) with DMSO. Surinabant plasma calibrators (5.00, 10.0,
50.0, 100, 250, 500, 750, 1.00 x 103 and 1.50 x 103 ng/ml) were prepared by
diluting the corresponding surinabant standard solutions in a 1:20 ratio with the
blank plasma. Surinabant plasma controls (7.50, 75.0, 150, 600, 750 and 1.20 x
103 ng/ml) were prepared by a 1:20 dilution of the corresponding surinabant
standard solutions with the blank plasma. All plasma samples were stored at –
20 C until use.

Surinabant Extraction from Plasma

Plasma samples (e.g., surinabant plasma calibrators, surinabant plasma
controls) were prepared using the following protocol. First, 200 µl of plasma
sample was pipetted into a 1.5 ml Eppendorf tube, then followed by 10.0 μl of the
AM251 working solution (5.00 μg/ml) and 50.0 μl of acetic acid. After vortex
mixing, 1.00 ml of acetonitrile was added. The solution was vortexed, then
centrifuged at 13,000 g for 15 min. After centrifugation, the supernatant was
transferred to a 1.5 ml Eppendorf tube, and evaporated to dryness in a TurboVap
LV Evaporator (Caliper Life Sciences, Hopinkton, MA, USA) at 55 ºC with N2
pressure of 20 psi for 2 h. Prior to analysis, 200 µl of mobile phase was added to
the dried samples.
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Surinabant Recovery from Plasma
The recovery of plasma surinabant by sample preparation procedure was
determined using surinabant plasma controls and surinabant reference solutions
at three different concentrations, which were 7.50, 75.0, 750 ng/ml for LC-ESIMS/MS and 150, 600 and 1.20 x 103 ng/ml for LC-UV. The reference solutions
contained the same sample matrix as that of plasma controls, which were
prepared using blank plasma as samples by the same sample preparation
procedure as that of plasma controls, and reconstituted in the mobile phase with
appropriate surinabant concentrations.

LC-UV Method

Instrumentation: A System Gold® HPLC BioEssential 126/128 from Beckman
Coulter (Fullerton, CA, USA) was used in this work, which consisted of a126gradient pump, a 508-autosampler and cooler that was set at ambient
temperature, a stainless steel in-line filter (0.5 μm pore, 0.23 μL dead volume)
from Upchurch Scientific (Oak Harbor, WA, USA), a YMCTM Pro C4 cartridge
column (3 µm, 120 Å, 2.0 mm x 50 mm) from Waters (Milford, MA, USA), a 168photo diode array detector the was set at 258 nm, and a 32-karat workstation.
The fluidic connection of the system was made using stainless steel tubing
(0.0625 in. o.d., 0.0100 in. i.d.). Data acquisition and peak integration was done
by 32-karat software (version 8.0). The peak area ratios of surinabant to the
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internal standard were plotted against plasma surinabant concentrations for a
calibration curve.
Chromatographic separation: Surinabant and AM251 were separated under
ambient temperatures on a Waters YMCTM Pro C4 cartridge column. Prior to the
analysis, the cartridge column was first equilibrated with the mobile phase
containing 99.9% CH3OH/H2O (50:50, v/v) and 0.1% HCOOH at a flow rate of
0.200 ml/min for about 30 min. In each analysis, 20 μl of sample was injected
with the autosampler, and the analytes were separated on the column by
isocratic elution at a flow rate of 0.200 ml/min.

LC-ESI-MS/MS Method

Instrumentation: The LC-ESI-MS/MS system used in this work consisted of
an HP1100 pump by Hewlett Packard (Palo Alto, CA, USA), an HP1100
autosampler, a stainless steel in-line filter (0.5 μm pore, 0.23 μl dead volume) by
Upchurch Scientific (Oak Harbor, WA, USA), a YMCTM Pro C4 cartridge column
(3 µm, 120 Å, 2.0 mm x 50 mm) by Waters (Milford, MA, USA), a stainless steel
splitting tee (1/16” x 0.25 mm) by Valco (Houston, TX, USA), and a Quattro II
electrospray ionization triple quadrupole mass spectrometer by Micromass
(Manchester, UK). All fluidic connections of the system were made using highpressure polyether ether ketone (PEEK) tubing (0.0625 in. o.d., 0.0100 in. i.d.).
The post-column split ratio was 1:2 with a smaller flow (ca. 63 μl/min) to the MS
detector and the larger one to the waste. Data acquisition and peak integration
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were accomplished using the Micromass Masslynx software (version 3.4). The
peak area ratios of surinabant to the internal standard were plotted against
plasma surinabant concentrations for a calibration curve.
Chromatographic separation: The separation conditions were the same as
those described in the Section 2.5.
ESI-MS/MS detection: The Micromass Quattro II triple quadrupole mass
spectrometer was operated under the positive electrospray ionization mode
(ESI+). Tuning of the mass spectrometer was accomplished by infusion of a
mixture of surinabant (2.0 μg/ml) and AM251 (2.0 μg/ml) in the mobile phase at a
flow rate of 3 μl/min with a syringe pump (Harvard Apparatus, South Natick, MA,
USA). Ionization conditions were optimized as follows: nitrogen sheath and
desolvation gas at 10 and 350 l/h, capillary at 3.5 kV, HV lens at 0.5 kV, cone at
45 V, skimmer at 1.5 V, RF lens at 0.2 V, ion source temperature at 95 C, ion
energy at 0.1 V, low- and high-mass resolution at 15, and multiplier at 700 V.
Full-scan spectra were acquired in the continuum mode at a scan rate 400 u/s.
Multiple reaction monitoring (MRM) mode was used for quantitation, which was
set at the following conditions: m/z 523 → 423 for surinabant, m/z 555 → 455 for
AM251, argon collision gas at 2.0-2.5 μbar, cone at 45 V, collision energy at 20 V
for both analytes, low- and high-mass resolution at 10 for quadrupole 1 and 15
for quadrupole 3, dwell time at 0.4 s, and the inter-scan delay at 0.01 s. The
ionization parameters were the same as those described previously.
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2.3.3 Results and Discussion

Calibrator and Control and Plasma Sample Preparation

When choosing a solvent for dissolution of analytes into a solution, there
are two key considerations; first, the solvent chosen must dissolve the compound
completely to produce a homogenous solution; secondly, the solvent should not
cause matrix precipitation upon its addition to biological samples. The chemical
structures of both surinabant and AM251 indicates that they are hydrophobic
compounds and are expected to have low solubilities in aqueous solution.
Therefore, it will not be possible to dissolve either compound directly in biological
samples.
Our previous experiments with rimonabant showed that protonation of amine
groups 0.1 M HCl had little effect on the water solubility of the compound. Since
surinabant has a similar structure with rimonabant which is completely soluble in
DMSO and the addition of DMSO at 25% or lower does not cause protein
precipitation in plasma [38], DMSO has been chosen as the solvent for the
preparations of surinabant and AM251 stock and working solutions, as well as
surinabant standard solutions. The percent composition of DMSO in surinabant
plasma calibrators and controls in this work was 10% (v/v) in which there was no
protein precipitation observed.
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Plasma samples were prepared by the protein precipitation procedure
described in section 2.2.2. The supernatant containing surinabant and AM251
was evaporated to dryness in a TurboVap LV Evaporator. The drying time may
be shortened by increasing either the temperature of the water bath or the
pressure of nitrogen flow. The sample preparation procedure used has been
proven by the recovery data (Table 1) to be adequate for the analysis of
surinabant by LC-UV and LC-ESI-MS/MS methods.

HPLC Method Using UV Detection

In this work, a Waters YMCTM Pro C4 column was used based on the success
of this column in the method developed for rimonabant. Although surinabant has
a smaller molecular weight than AM251, the presence of an ethyl group at the 4position of its pyrazole ring causes surinabant to be more hydrophobic than
AM251. The elution sequence from a C4 column was AM251 (7.4 min) first, then
surinabant (9.4 min), and the total run time for each sample was about 11.0 min.
Both surinabant and AM251 showed maximum absorptivity at 258 nm and no
detectable interference from the blank human plasma was present in this range.
Therefore, the signal at 258 nm was used for quantitation.
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Figure 2.18, Chromatogram of surinabant (500 ng/mL) and AM251 (250
ng/mL)
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The recovery of surinabant was ascertained using the protein precipitation
procedure and LC-UV method with surinabant plasma controls and surinabant
reference solutions at three different concentrations (150, 600 and 1.2 x 10 3
ng/mL). The relative recoveries of surinabant were determined by comparing the
mean-peak-area ratios of surinabant to the internal standard in the plasma
controls to those of surinabant to the internal standard in the reference solutions.
As discussed in section 2.2.3, the recovery should be consistent across the
concentration range of interest.
The precision of the LC-UV method was established by analyzing surinabant
plasma controls at three different concentrations (150, 600 and 1.2 x 10 3 ng/mL)
and was determined by the duplicate measurements of the peak-area ratio of
surinabant to the internal standard from five separate samples at each
concentration.

The ability of the LC-UV method to accurate measure the

concentration of surinabant was also established using the low, middle and high
concentrations used to determine precision.

The recovery, precision and

accuracy of the LC-UV method is contained in table VII.

The data provided in

this table indicates exceptional analytical performance of the LC-UV method to
measure surinabant in human plasma.
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Table VIII, Analytical performance of the HPLC-UV method

[Surinabant]
(ng/mL)

Recovery (%)

Standard
Deviation

CV (%)

Accuracy (%)

150

103%

0.0099

3.0%

87%

600

95.0%

0.0535

3.9%

97%

1.20 x 103

97.0%

0.0857

3.1%

93%

All determinations were based on the mean value obtained from five (5) separate samples at
each concentration. The concentration of internal standard was fixed (250 ng/mL)
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The linear response of the LC-UV method was determined by plotting the
internal standard corrected surinabant peak-area versus the concentration of
surinabant calibrator.

A linear calibration range of 100-1500 ng/ml with a

correlation coefficient of 0.999 was achieved.

A calibration equation, y =

0.00232x – 0.0619, was derived from the average peak area ratio of two
separate injections from a single sample at each of the six concentrations (100,
250, 500, 750, 1000 and 1500 ng/ml) over the calibration range.

A second

condition which was not discussed in section 2.2.3 for the identification of the
lower limit of quantification (LLOQ) suggested by the FDA guidelines is that the
precision and accuracy of this measurement fall within a 20% error range. The
LLOQ of the LC-UV method was determined by the lowest plasma surinabant
calibrator on the calibration curve to be 100 ng/ml with a CV and an accuracy of
8.0 and 95.0%, respectively.

HPLC Method with Mass Spectrometric Detection

In the LC-ESI-MS/MS method, the chromatographic separation conditions
were the same as those described in the LC-UV method. However, because the
fluidic connection of this system included a post column splitter, the elution times
of AM251 and surinabant were slightly longer than (ca. 0.9 min) those of the LCUV method. A post-column splitter is required to divert a portion of the sample
flow to waste; thereby assuring that the flow rate entering the MS is under the
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100 μL/min discussed in section 1.5.2.

The total run time for each sample was

approximately 12.0 min.
The full-scan mass spectra by positive electrospray ionization revealed
that surinabant and AM251 produced predominant protonated molecular ions at
m/z 523 and 555, respectively. These parent ions were fragmented to produce
daughter mass spectra which resulted in predominant product ions at m/z 423 for
surinabant and m/z 455 for AM251.
As with the method for rimonabant, these product ions were measured by
the multiple-reaction-monitoring (MRM) mode for internal calibration and
quantitation of surinabant. The selectivity and specificity of the LC-ESI-MS/MS
method by MRM mode for the measurement of surinabant and AM251 is
illustrated by the mass chromatograms contained in figure 2.20 which show no
interference from the plasma matrices.
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(A)

(B)

(C)

(D)

Figure 2.19. (A) Full scan of surinabant, (B) daughter ions of surinabant, (C)
full scan of AM251 and (D) daughter ions of AM251
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Figure 2.20, Representative mass chromatograms of surinabant and AM251
in (A) blank plasma, (B) plasma treated with AM251 (250 ng/mL) only and (C)
plasma treated with both surinabant (500 ng/mL) and AM251 (250 ng/mL)
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The fragmentation of surinabant produced a predominant product ion of 100
amu less than its parent ion, a pattern identical to that rimonabant and AM251
described in our previous work.

Therefore, the fragmentation reaction of

surinabant could be proposed and is contained in figure 2.21.
The recovery of surinabant was established using the protein precipitation
procedure and LC-ESI-MS/MS method previously described with surinabant
plasma

controls

and

surinabant

reference

solutions at

three

different

concentrations (7.50, 75.0 and 750 ng/ml). The precision (%CV) and accuracy
was determined by the triplicate measurements of the peak area ratio of
surinabant to the internal standard from five separate samples at each of the
three concentrations listed above.

The method for calculating for these

parameters has been previously discussed.

The recovery, precision and

accuracy values are reported in Table VIII.
The linear calibration range of the LC-ESI-MS/MS method was 5.00 to
1000 ng/ml with a correlation coefficient of 0.999. A calibration equation, y =
0.00373x – 0.00941, was derived from the average peak area ratio of three
separate injections from a single sample at each of the six concentrations (5.00,
10.0, 50.0, 100, 500 and 1000 ng/ml) over the calibration range. The LLOQ for
the LC-ESI-MS/MS method was determined to be 5.00 ng/ml with a CV and an
accuracy of 6.0 and 90.9%, respectively.
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Figure 2.21, Proposed fragmentation scheme of surinabant
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Table IX, Analytical performance of HPLC-MS method

[Surinabant]
(ng/mL)

Recovery (%)

Standard
Deviation

CV (%)

Accuracy (%)

7.50

101%

2.60 x 10-3

7.7%

92%

75.0

96.0%

0.009

2.9%

87%

750

100%

0.145

5.7%

93%

All determinations were based on the mean value obtained from five (5) separate samples t
each concentration. The concentration of internal standard was fixed (250 ng/mL)
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Surinabant Stability

The stability of surinabant in plasma was established by three aliquots at
each low and high controls. As with rimonabant, all error reported refers to the
difference between the condition the sample was exposed to and time zero.
After three freeze (−20 C) and thaw (room temperature) cycles, a maximum
relative error of 6% was observed.

The short-term temperature stability of

surinabant in plasma was established by storing the surinabant plasma controls
at room temperature for 24 h with the maximum relative error observed being
4%. A study was conducted to determine the necessity of storing surinabant
samples in amber vials to protect the compound from light degradation.
Surinabant plasma controls stored in amber versus clear vials for six weeks at 20 C gave a maximum relative error of 7% which showed that surinabant could
be stored safely under these conditions without protection from light. Overall, in
all situations investigated, surinabant exhibits sufficient stability.

2.3.4 Conclusion

Two methods, an LC-UV and an LC-ESI+-MS/MS method have been
developed and validated for the quantitative measurement of surinabant in
human plasma using AM251 as the internal standard. A protein precipitation
procedure using acetonitrile was established, which resulted in consistent
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recovery of surinabant. A LLOQ of 100 ng/ml and a calibration range of 1001500 ng/ml was obtained for surinabant. LC-ESI-MS/MS detection had a LLOQ
of 5.00 ng/ml and a calibration curve of 5.00-1000 ng/ml for surinabant.

Both

methods developed exhibited strong analytical performance which is validated by
the recovery, precision and accuracy of the methods to measure surinabant.
The low limits of detection achieved with these methods permits their application
to a variety of studies involving the pharmacology, toxicology and biochemical
mechanisms of surinabant.
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CHAPTER III

PRELIMINARY WORK CONDUCTED TO DEVELOP
BIOANALYTICAL METHODS FOR THE MEASUREMENT OF ANTI-CANCER
AGENTS, QUINACRINE AND TRIAPINE

3.1 Quinacrine

3.1.1 Introduction

Quinacrine is a drug with a long history and broad, interesting therapeutic
applications. The chemical structure of quinacrine is contained in figure 3.1. It
was first used in the 1930‟s as an antimalarial compound [1]. Over the years it
has also been used to treat infections of the parasite Giardia [2].

146

Figure 3.1, Chemical structure of quinacrine

147

A controversial, but common use of quinacrine is to cause female sterilization;
primarily in poor, underdeveloped and overpopulated areas [3]. Quinacrine has
also offered hope for the currently, untreatable, condition of prion disease [4].
Finally, quinacrine has shown promise as an anti-cancer agent [5]. The recent
interest in the use of quinacrine for the treatment of both prion disease and
cancer resulted in an anticipated need for a bioanalytical method to measure this
compound, which led to the preliminary steps presented in this work.
The role of quinacrine in the treatment of cancer revolves around its ability to
inhibit tumor protein 53 (p53) [6]. P53 is transcription factor which is present on
both tumor and non-tumor cells. In tumor cells, p53 is generally inactivated.
Therefore, typical cancer therapy‟s cause tumor cells die via non-apoptotic
processes. On the contrary, normal tissues undergo a high rate of apoptosis
during cancer treatment which is responsible for the deteriorative, adverse side
effects. Research has shown that quinacrine can serve as a p53 activator,
thereby re-establishing the ability of tumor cells to undergo apoptosis [6] [7]. In
this sense, quinacrine is able to sensitize the tumor cells to an increased death
rate of these cells.
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Figure 3.2, Block diagram describing the role of quinacrine in cancer
treatment
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There is no current pharmacological treatment for prion disease; a severe,
progressive, neurological disorder. Prion disease is caused by the propagation
of a misfolded prion protein, PrP. PrPSC is the isoform of PrP which is indicated
in prion disease. PrPSC converts the structure PrP to the infectious PrPSC form.
Quinacrine is able to block the conversion of PrP to PrPSC in vitro [8]. It should
be mentioned that neither the mechanism involved in the structural change from
PrP to PrPSC, nor quinacrines ability to inhibit it; is well understood.
In 2004 research was published which established an HPLC-MS/MS
method for the measurement of quinacrine [9]. The research described paints an
initial pharmacokinetic profile of quinacrine as it relates to the treatment of prion
disease. The study published in this article provides a strong stepping stone for
the measurement of this compound. However, the work was lacking many
features which are critical to demonstrating the performance of a quantitative
bioanalytical method. Notably, there lacked a discussion regarding the sample
extraction methods and validation of the ability of the method to measure
quinacrine.
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3.1.2 Materials and Methods

Reagents

Acetic acid, HPLC-grade acetonitrile and methanol, dimethyl sulfoxide
(DMSO), and formic acid, ammonium acetate and quinacrine were purchased
from Sigma-Aldrich (St. Louis, MO, USA). The internal standard, NCI number
10593-V/2 was provided, at no cost, by National Cancer Institute Drug
Depository
The quinacrine stock solution (1.00 mg/ml) was prepared by weighing 0.85
mg of the compound into a 1.5 ml Eppendorf tube (Eppendorf, Westbury, NY,
USA) and dissolving it with 0.85 ml of MeOH:H2O (50:50 v/v). A stock solution
(1.00 mg/ml) of 10593-V/2 was prepared by weighing 1.20 mg of the compound
into a 1.5 mL Eppendorf tube and dissolving it with 1.20 ml of MeOH:H2O (50:50
v/v).
Once the compounds were dissolved, both quinacrine and the internal
standard stock solutions were transferred to 1.5 ml amber glass autosampler
vials, sealed with parafilm, and were stored at - 20 ºC when not in use.
Quinacrine and internal standard working solutions (100 μg/ml) was prepared by
a dilution (1/10) of the stock solution with MeOH:H2O (50:50 v/v). A mobile phase
for liquid chromatographic separation was prepared by first adding ammonium
acetate to water. The ammonium acetate/H2O solution was mixed with methanol
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(50% v/v) with the ammonium acetate concentration being 5mM of the final
mobile phase volume. All solutions were stored at 4◦C when not in use.

Instrumental Setup

The instrumental setup used in this work consisted of an HP1100 pump by
Hewlett Packard (Palo Alto, CA, USA), an HP1100 autosampler, a stainless steel
in-line filter (0.5 μm pore, 0.23 μl dead volume) by Upchurch Scientific (Oak
Harbor, WA, USA), a Oasis HLB cartridge column (2.1 mm x 20 mm) by Waters
(Milford, MA, USA), and a HCT ion trap mass spectrometer by Bruker Daltronics
(Billerica, MA, USA). All fluidic connections in the system were made using highpressure polyether ether ketone (PEEK) tubing (0.0625 in. o.d., 0.0100 in. i.d.).

HPLC Separation

Analytical separation was performed via a Oasis HLB cartridge column (3
μm, 120 Å, 2.0 mm x 50 mm) by Waters (Milford, MA, USA). Before analysis, the
cartridge column was equilibrated with mobile phase at a flow rate of 0.100
ml/min for about 20 min. During the analyses, 20 μl of sample was injected by the
autosampler and carried onto the cartridge column by the mobile phase at a flow
rate of 0.100 ml/min. Under the conditions described above, quinacrine and the
internal standard had a retention times of 3.5 and 3.8 minutes, respectively.
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MS Detector Settings

A Bruker HCT ion trap mass spectrometer was used for the detection of
quinacrine and the internal standard, 10953-V/2. The IT-MS parameters used
were as follows: positive polarity, a capillary voltage of -4500 V, nebulizer gas
pressure of 35 psi, drying gas flow or 9.0 L/min, a drying gas temperature of
340°C, and a fragmentation amplitude of 0.6V. The IT-MS was operated in ultra
scan mode to provide optimum resolution and sensitivity.

3.1.3

Discussion

The focus of the work here was primarily to determine whether an on-line
sample extraction would be possible for the measurement of quinacrine in
biological matrices. As discussed in Chapters I and II, on-line sample extraction
has many advantages over traditional, LLE, protein precipitation and SPE
procedures.
The development of an HPLC separation method was investigated using a
Waters Oasis HLB column. An IT-MS was used for the detection of quinacrine
and the internal standard. The internal standard, identified as 10593-V/2, was
provided by the National Cancer Institute Drug Repository Program, the chemical
structure is contained in figure 3.3.
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Mass Spectrometric Detection

As evidenced by the chemical structure of quinacrine, there are several
nitrogen groups which may be protonated. When a compound exists in several
ionic forms, the mass spectrometric sensitivity can be compromised. As
discussed in Chapter I, the MS detector reports a signal based on the m/z ratio of
the analyte. Multiple charged species result in several m/z ratios being attributed
to a single analyte mass. When conducting quantitation using MRM mode, only
one m/z ratio is selected to undergo isolation and fragmentation. As predicted by
the chemical structure, a full scan of quinacrine revealed the presence of two
molecular ions; the singly protonated ion at m/z 400 and the doubly protonated
species at m/z 200.6 (figure 3.4).
The solvent used to dissolve quinacrine which resulted in the spectra
contained in figure 3.4 was a 50:50 mixture of MeOH:H2O, 0.3% formic acid, pH
4.0. In order to preferentially select for the singly protonated form of quinacrine,
several mobile phase compositions were tested. The solvent chosen to dissolve
quinacrine was 50:50 mixture of MeOH:H2O, 5mM ammonium acetate, pH 5.8.
Figure 3.5 contains the full scan spectra of the predominantly singly protonated
ions of quinacrine and the internal standard
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standard
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Daughter ion spectra of quinacrine and the internal standard are contained in
figure 3.6. The fragments selected for the detection of quinacrine and the
internal standard in subsequent analysis were m/z 244 for quinacrine and m/z
403 for 10593-V/2, the internal standard.
Mass chromatograms for quinacrine and the internal standard are exhibited
in figure 3.7. Using the HPLC-MS parameters discussed, a calibration curve was
obtained for quinacrine standards with the linear range of 50 – 2000 ng/mL and a
correlation coefficient of 0.999.

Analyte Extraction via On-line Sample Extraction

The Waters Oasis HLB is marketed for its ability to work well in the design
an on-line extraction procedure. In this case, the idea is that plasma containing
quinacrine can be directly injected onto the column; quinacrine would be retained
by the column, while the plasma proteins and other matrix components would
travel to waste. This is accomplished by using a column switch to alternate
between the column elutent flowing to waste or to the mass spectrometer. A flow
diagram of the set up of one example of a fluidic profile tested is contained in
figure 3.8.
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Figure 3.6 Daughter ion spectra of (A) quinacrine and (B) 10593-V/2, the
internal standard
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Figure 3.7, Mass chromatograms of (A) quinacrine and (B) 10593-V/2
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As evidenced in figure 3.8, initially the aqueous mobile phase flows at 200
μL/min for 1.0 minutes to load the sample onto the column. Next, the flow is kept
constant and a mobile phase with a 50% organic composition is introduced to the
column. During this step, quinacrine is retained by the column while the matrix
components are diverted to waste. Thirdly, the column switch changes the flow
so that the column elutent is able to travel to the MS detector. It is during this
time that the analyte is eluted from the column and subsequently detected. The
next two steps involve regenerating the aqueous solvent through the column at a
high flow rate and finally, reducing the flow of the aqueous solvent to allow for
pressure equilibration.
Quinacrine is a hydrophobic compound which resulted in it being retained so
strongly by the HLB column that a high degree of carryover occurred between
analyses. The carryover dilemma resulted in the feasibility of on-line extraction
being abandoned. Without the development of an on-line extraction procedure,
the further investigation into developing a quantitative bioanalytical method for
quinacrine was not warranted.
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Figure 3.8, Fluidic profile for on-line sample extraction of quinacrine
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3.2 Triapine

3.2.1 Introduction

Triapine (3-AP) is a relatively new compound being investigated for use as an
anti-cancer therapy [10]. The chemical structure of 3-AP is contained in figure
3.9. Vion Pharmaceuticals is developing 3-AP which is currently in both Phase I
[11] [12] [13] and II [14] clinical trials.
Cancer is caused by the uncontrolled proliferation of tumor cells.
Ribonucleotide reductase (RNR) is an enzyme which affects cellular proliferation
both by catalyzing the transformation of ribonucleotides (NTP‟s) to
deoxyribonucleotides (dNTP‟s), the building blocks of DNA; as well as by
involvement in the DNA repair process [15]. 3-AP belongs to a class of
compounds referred to as RNR inhibitors [16].
The ability of 3-AP to inhibit the conversion of NTP‟s to dNTP‟s effectively
halts cellular proliferation and thus, the development of tumors. It has been
reported that the ability of 3-AP to inhibit RNR lies in the metal chelating
properties of 3-AP [15]. Chelation involves the ability to a ligand such as 3-AP to
form complexes with metal ions.
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Figure 3.9, Chemical structure of 3-AP
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RNR is an iron dependant enzyme which catalyzes the reaction of NTP‟s
to dNTP‟s via a free radical reaction. This reaction occurs at the active site of the
protein molecule which contains an iron, essential to the enzyme function.

It

has been suggested that the ability of triapine to inhibit this process is related to
3-APs involvement with the iron in the active site of RNR.
As mentioned, 3-AP is a new cancer treatment which is the subject of heavy
clinical investigation. Currently there are no publicly available bioanalytical
methods for the measurement of 3-AP. Thus, the development of such method
is of strong importance.

The scope of this work encompasses: the preliminary

data obtained for the detection of triapine using HPLC-MS methods; the
challenges faced; and suggestions for the future development of this method.
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3.2.2 Materials and Methods

Reagents

Acetic acid, HPLC-grade acetonitrile, dimethyl sulfoxide (DMSO), and formic
acid, were purchased from Sigma-Aldrich (St. Louis, MO, USA). 3aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine or 3-AP) was
provided, at no cost, by Vion Phamaceuticals (New Haven, CT, USA).
Thioacetazone, the internal standard, was provided at no cost from the National
Cancer Institute Drug Depository (NCI reference #3550).
The 3-AP stock solution (1.00 mg/ml) was prepared by weighing 1.28 mg of
the compound into a 1.5 ml Eppendorf tube (Eppendorf, Westbury, NY, USA)
and dissolving it with 1.28ml of solvent (either DMSO or a MeOH:H2O mixure). A
stock solution (1.00 mg/ml) of thioacetazone was prepared by weighing 1.45 mg
of the compound into a 1.5 mL Eppendorf tube and dissolving it with 1.45 ml of
solvent.
Once the compounds were dissolved, both 3-AP and internal standard stock
solutions were transferred to 1.5 ml amber glass autosampler vials, sealed with
parafilm, and were stored at - 20 ºC when not in use. 3-AP working solutions
(100 μg/ml) was prepared by a dilution (1/10) of the 3-AP stock solution with
solvent. A mobile phase for liquid chromatographic separation was prepared by
first adding formic acid (HCOOH) to water. The formic acid/H2O solution was
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mixed with methanol (35% v/v) with the HCOOH concentration being 0.1% of the
final mobile phase volume. All solutions were stored at 4 ◦C when not in use.

Instrumental Setup

The instrumental setup used in this work consisted of an HP1100 pump by
Hewlett Packard (Palo Alto, CA, USA), an HP1100 autosampler, a stainless steel
in-line filter (0.5 μm pore, 0.23 μl dead volume) by Upchurch Scientific (Oak
Harbor, WA, USA), a YMC™Pro C18 cartridge column (3 μm, 120 Å, 2.0 mm x
50 mm) and YMC™Pro C18AQ cartridge column column (3 μm, 120 Å, 2.0 mm x
50 mm) by Waters (Milford, MA, USA), a stainless steel splitting tee (1/16” x 0.25
mm) by Valco (Houston, TX, USA), and a Quattro II triple quadrupole mass
spectrometer by Micromass (Manchester, UK). All fluidic connections in the
system were made using high-pressure polyether ether ketone (PEEK) tubing
(0.0625 in. o.d., 0.0100 in. i.d.). The post-column split ratio was 1:2 with a smaller
flow (ca. 63 μl/min) to the MS detector and the larger one to the waste.

HPLC Separation

Analytical separation was performed via a Waters YMC™Pro C18 or
YMC™Pro C18AQ cartridge column. Before analysis, the cartridge column was
equilibrated with mobile phase at a flow rate of 0.100 ml/min for about 20 min.
During the analyses, 20 μl of sample was injected by the autosampler and
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carried onto the cartridge column by the mobile phase at a flow rate of 0.200
ml/min. Under the conditions described above, 3-AP had a retention time of 2.75
minutes.

MS Detector Settings

Electrospray ionization mode (ESI+) was utilized on the Micromass Quattro II
triple quadrupole mass spectrometer. Tuning of the mass spectrometer was
achieved by infusion of a 3-AP (10.0 μg/ml) in the mobile phase at a flow rate of
3.0 μl/min with a syringe pump (Harvard Apparatus, South Natick, MA, USA).
Optimal ionization conditions were as follows: nitrogen sheath and desolvation
gas at 10 and 350 l/h, capillary at 3.5 kV, HV lens at 0.5 kV, cone at 30 V,
skimmer at 1.5 V, RF lens at 0.2 V, ion source temperature at 80◦C, ion energy at
1.0 V, low- and high-mass resolution at 10, and multiplier at 700 V. Full-scan
spectra were acquired in the continuum mode at a scan rate 400 u/s. The
instrument was operated in multiple reaction monitoring (MRM) mode for
quantitation, which was set as follows: m/z 196 → 94 and 196 → 120 for 3-AP,
argon collision gas at 2.0-2.5 μbar, cone at 30 V, collision energy at 30 V, lowand high-mass resolution at 10 for quadrupole 1 and 10 for quadrupole 3, dwell
time at 0.4 s, and the inter-scan delay at 0.01 s. The parameters for ionization
remained the same as previously discussed.
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3.2.3

Discussion

Sample Preparation

As discussed 3-AP is a metal chelator, therefore precautions should be taken
to avoid the introduction of metals to the analyte when preparing stock solutions.
A wooden or plastic was employed for the removal and weighing of 3-AP, but the
challenge remains to reduce the contact of 3-AP with metal ions throughout
sample preparation and analysis.
A common approach to avoid unwanted interactions of an analyte that is a
metal chelator is the use of a stronger chelator, such as
ethylenediaminetetraacetic acid (EDTA). EDTA can be added to stock solutions
and mobile phases in order to preferentially bind with any metals, thus leaving 3AP unreacted and detectable. In the case of HPLC-UV methods, EDTA is a
common additive and has little effect of the sensitivity of the method. However,
in HPLC-MS, the detection of analyte is depending on ionization, as discussed in
Chapter 1.
The use of any additive in mass spectrometry, including EDTA; can
negatively impact the sensitivity of the method based on the ion suppression
theory. Ion suppression is a type of matrix effect caused when there is an
excess of ionizable molecules eluted from the HPLC system concurrently with
the analyte molecules. A graphical representation of ion suppression is
contained in figure 3.12.
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To understand ion suppression, it is helpful to consider that at during any
given timeframe, there only exists enough electrical current to ionize a fixed
amount of molecules. In figure 3.12(A) which represents ideal ionization, the
entire electrical field is able to be applied to the analyte, depicted in red.
However, if elution from the HPLC results in matrix components present during
the ionization of the analyte, only a fraction of the molecules ionized and
thereafter detected, will be analyte molecules. In this sense, ion suppression
diminishes the sensitivity of the method being developed.
The suppression is exasperated in any matrix component which is more
easily ionized than the analyte molecules, which is often the case when EDTA is
used. Therefore, if EDTA is employed as an additive, consideration must be
taken to determine the ratio between the amounts which are beneficial versus the
amount which causes detriment to the detection of the analyte.
A final aspect of 3-AP sample preparation is the ability of the compound to
dissolve. As expected from the chemical structure, 3-AP is not water soluble.
Further 3-AP has a pKa of 4.2 which indicates that it will exist in a protonated
form at a pH less than 4.2. Several solvent compositions were tested for their
ability to dissolve 3-AP. DMSO readily dissolves the compound; however, in
order to achieve control of the pH, the solvent composition should have an
aqueous component. Both 50% DMSO and 50% MeOH in H2O, adjusted to pH
4.0 with formic acid are able to dissolve 3-AP. It is important to note that the
addition of an acidic component to the solvent causes a dramatic increase (10
fold) in the bright yellow color observed.
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Mass Spectrometric Detection

The first step in the development of an HPLC-MS method is to optimize the
ionization, fragmentation and detection parameters of the MS instrument. This
process was undertaken by infusion of 10 μg/mL of the analyte dissolved in a
solution of 50% MeOH in H2O, adjusted to a pH of 4.0. Figure 3.13 contains the
full scan and daughter ion spectra for 3-AP. The instrument used for the
detection of 3-AP was a Quattro II triple quadrupole mass spectrometer by
Micromass.
As evident in figure 3.13(A), the predominant analyte ion is present at the m/z
of 196, which represents the singly protonated 3-AP molecule. Fragmentation of
the ion at m/z of 196 results in two predominant daughter peaks; m/z 94 and m/z
of 120. The ratio of daughter peaks is variable depending primarily upon the
collision gas pressure.
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Figure 3.13, (A) full scan, and (B) daughter spectra of 3-AP
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Figure 3.14 contains mass chromatograms of the total ion signal due to the
ion with the m/z ratio of 196, and the extracted signal of the daughter ions at both
m/z 94 and 120. It is evident in this figure that a significant portion of the total
signal is due to the signal of both daughter ions. These mass chromatograms
were obtained using the following HPLC parameters: a Waters YMC Pro C18
column; a mobile phase composition of 35% MeOH in H2O adjusted to a pH of
4.0 with formic acid; a flow rate of 100 μL/min with a post column splitter diverting
2/3rds of the flow to waste.
Figure 3.15 contains mass chromatograms of stock solutions of 3-AP ranging
from1.00 ng/mL to 100 ng/mL. For the purpose of the current clinical
investigations, it is expected that a detection limit in the range of 1 ng/mL will be
required to precisely and accurately measure 3-AP in human plasma. As
evidenced by this figure, the sensitivity achieved with efforts to date, are not
sufficient to continue forward with steps to develop a procedure for extraction of
3-AP from a plasma matrix.
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Figure 3.14, Extracted ion chromatogram for 3-AP of (A) daughter ion m/z 94,
(B) daughter ion m/z 120 and (C) the total ion chromatogram of 3-AP which
(A) and (B) were extracted from
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178

Time

3.2.4 Challenges and Future Direction for The Development of a Quantitative
Bioanalytical Method to Measure 3-AP

The challenges faced during the preliminary development of a
bioanalytical method for the measurement of 3-AP were centered on two major
hurdles: first, the nature of 3-AP as a metal chelator; and secondly, the apparent
resistance of 3-AP to electrospray ionization.

Metal Chelation

As discussed, 3-AP is a metal chelator and the current approach to
analysis of this compound requires that it remain in a non-chelated, free form.
While the introduction of metal ions can be avoided in many respects, the design
of modern instruments involves a substantial amount of metal components. The
interaction with the analyte cannot be avoided in these instances.
One solution to the metal chelation challenge is to employ the use of
stronger chelating compounds in the preparation of stock solutions and mobile
phases. EDTA is one such compound, but its use is a “double-edged sword”; the
benefits afforded by its chelating power may be outweighed by the ion
suppression it causes.
The first step in overcoming any challenge that metal chelation poses in
the development of this method would be to conduct a systematic study using
EDTA as an additive at varying ratios to 3-AP. Further, alternative chelating
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agents such as nitrilioacetic acid (NTA) may be investigated as superior
substitutes to EDTA.

Ionization

It is not possible to develop a successful quantitative bioanalytical method
using HPLC-MS without ionizing the compound to be analyzed. Great detail was
provided in Chapter I regarding the importance of ionization and the various ion
sources commercially available. Often the chemistry of a compound leaves it
resistant to the acceptance (or loss of) a proton. Additionally, it is not uncommon
for a compound to undergo substantial fragmentation during the ionization
process.
In the case of 3-AP, the resistance of the compound to protonation should
be investigated. As previously discussed, 3-AP has a pKa of 4.2, and the
dissolution of the compound in acidic solutions generates a strong color change.
It is possible that once triapine undergoes the initial protonation in the dissolution
process, that the resulting chemical structure is stabilized in a neutral form and
that the normal ESI process is unable to protonate the analyte further. In this
case, it should be investigated whether the acidic conditions during sample
preparation are required for 3-AP to dissolve.
In some instances; it is not a chemical resistance to protonation which
causes a lack of ions for analysis, but a disintegration of the analyte material
during ionization. As described in Chapter I, the ESI process can be enhanced
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through the introduction of a nebulizing gas such as nitrogen. The pressure of
this nebulizing gas is a parameter which should be optimized to achieve
maximum ionization.
However, it is not only the gas pressure which can prematurely fragment and
render an analyte undetectable. In some situations, the chemical structure of a
compound is such that the desolvation process itself creates instability and
results in unwanted fragmentation. Typically, ESI is the ionization process of
choice due to the balance between its gentle yet powerful mechanism. For 3-AP,
it would be useful to investigate the benefit of an alternate, even softer ionization
source such as APCI.

Conclusion

Mass spectrometry is one of the most sensitive detection methods available
to the analytical chemist. It is impossible to establish the underlying cause for
the inability of this technique to perform in the detection ranges expected with the
experiments‟ conducted with 3-AP to date. Two directions have been proposed
to increase the detection ability of the mass spectrometer for this compound.
Overall success may not come from taking just one route and may involve a
modulation of both.
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